Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1

2 Mixed methods systematic review and metasummary about barriers and facilitators
3 for the implementation of cotrimoxazole and isoniazid – preventive therapies for people living
4 with HIV.

5

6 Pia Müller ¹, Luís Velez Lapão ²

7 ¹ Global Health and Tropical Medicine, Universidade Nova de Lisboa, Instituto de Higiene e
8 Medicina Tropical, Lisbon, Portugal

9 ² Global Health and Tropical Medicine, Universidade Nova de Lisboa, Instituto de Higiene e
10 Medicina Tropical, Lisbon, Portugal

11

12

13

14

15

16 * Corresponding author

17 Email: pia.muller@ihmt.unl.pt (PM)

18 PM and LVL contributed equally to this work.

19

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

20 Abstract

21 **Background:** Cotrimoxazole and isoniazid preventive therapy (CPT, IPT) have been shown
 22 to be efficacious therapies for the prevention of opportunistic infections and tuberculosis (TB)
 23 among people living with human immunodeficiency virus (HIV). Despite governments' efforts
 24 to translate World Health Organization recommendations into practice, implementation
 25 remains challenging. This review aimed to explore and compare CPT and IPT with respect
 26 to similarities and differences of barriers identified across high TB/HIV burden countries. A
 27 secondary objective was to identify facilitators for implementing both preventive therapies.

28 **Methods:** We searched MEDLINE, Web of Science and SCOPUS databases for peer-
 29 reviewed literature published before September 2020. We extracted and synthesized our
 30 findings using Maxqda software. We applied framework synthesis in conjunction with
 31 metasummary to compare both therapies with respect to similarities and differences of
 32 barriers identified across seven health system components (in line with the modified WHO's
 33 Framework for action). Protocol registration: PROSPERO (CRD42019137778).

34 **Findings:** We identified four hundred and eighty-two papers, of which we included forty for
 35 review. Although most barrier themes were identical for both preventive therapies, we
 36 identified seven intervention-specific themes. Like for CPT, barriers identified for IPT were
 37 most frequently classified as 'service delivery-related barriers' and 'patient & community-
 38 related barriers'. 'Health provider-related barriers' played an additional important role for
 39 implementing of IPT. Most facilitators identified referred to health system strengthening
 40 activities.

41 **Conclusions:** For researchers with limited working experience in high TB/HIV burden
 42 countries, this review can provide valuable insights about barriers that may arise at different
 43 levels of the health system. For policymakers in high TB/HIV burden countries, this review
 44 offers strategies for improving the delivery of IPT (or any newer therapy regimen) for the

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

45 prevention of TB. Based on our findings, we suggest initial and continuous stakeholder
46 involvement, a focus on the efficient use and reinforcement of existing resources for health.

47 **Key words:** Implementation, HIV, Tuberculosis, Cotrimoxazole, Isoniazid, Systematic
48 review, Metasummary, Health systems strengthening, Global Health

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Introduction

Background

In 2019, 38 million people worldwide were living with the human immunodeficiency virus (HIV) [1]. An estimated quarter of the world's population was latently infected with *Mycobacterium tuberculosis*; 10 million developed active tuberculosis (TB) [2, 3]. The fact that HIV-positive individuals have 20 times higher risk of developing active TB disease compared to HIV-negative individuals has been described as a lethal combination [4], which has transformed many low- and middle-income countries (LMIC) into countries with a high dual burden of TB and HIV [2]. The latest UNAIDS report continues to present TB as the leading cause of death among people living with HIV (PLHIV), accounting for around one in three AIDS-related deaths worldwide [1]. This review focuses on the implementation of two of the most important preventive therapies for PLHIV in countries with a high burden of TB/HIV: cotrimoxazole (CTZ) and isoniazid (INH).

Cotrimoxazole (CTZ) is a fixed-dose combination of trimethoprim/ sulfamethoxazole that combines broad antimicrobial activity with immunomodulatory properties. Besides preventing some AIDS-associated opportunistic diseases (*Pneumocystis jirovecii* pneumonia (PCP), toxoplasmosis), CTZ has shown to be successful in reducing malaria, severe bacterial infections, and mortality among PLHIV. As a result, World Health Organization (WHO) recommends cotrimoxazole preventive therapy (CPT) lifelong for PLHIV in resource-limited settings where malaria and, or severe bacterial infections are highly prevalent, irrespective of their CD4 count. In settings where neither malaria nor severe bacterial infections are highly prevalent, CPT is recommended for PLHIV with severe or advanced HIV disease (WHO clinical stage 3 or 4, or CD4 count below 350 cells/mm³), and may be discontinued for those with evidence of immune recovery or viral suppression on antiretroviral treatment (ART). Adults, including pregnant women, children and adolescents

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

with HIV, and HIV-exposed but uninfected infants, as well as PLHIV with active TB, are eligible for CPT, including those concurrently receiving ART [5].

Isoniazid (isonicotinylhydrazide or INH) is the most common type of TB preventive therapy. With its anti-mycobacterial activity, isoniazid monotherapy is prescribed to treat latent TB infection and prevent the progression from latent to active TB. WHO recommends at least six months of isoniazid preventive therapy (IPT) to people at risk of TB living in resource-constrained and high TB and HIV prevalence settings. PLHIV comprise a major risk group for TB, among which IPT has shown to reduce TB disease and mortality irrespective of receiving ART. Therefore, PLHIV unlikely to have active TB, are eligible for IPT. This includes HIV-positive positive adults including pregnant women, adolescents, infants aged under 12 months who are in contact with a TB case, and children older than 12 months who have no contact with a TB case. HIV-negative children aged under 5 years who are household contacts of people with bacteriologically confirmed pulmonary TB comprise another target group for IPT. Independent of the target group, only people with unknown or a positive tuberculin skin test (TST) unlikely to have active TB are eligible for IPT. In the absence of TST, patients should be screened for TB according to a clinical algorithm. Those who do not report any of the symptoms of current cough, fever, weight loss or night sweats are unlikely to have active TB and should be offered preventive therapy, irrespective of the degree of immunosuppression and including those who have previously been treated for TB [4].

Rationale

Data from clinical trials and observational studies demonstrated that both preventive therapies are well-tolerated, highly efficacious, and cost-effective among PLHIV [6-10], resulting in WHO recommendations that were first adopted almost two decades ago [11, 12]. With increasing evidence supporting the benefits of the preventive therapies for PLHIV, WHO recommendations have been even expanded with regard to therapy duration and target populations indicated for CPT and IPT in today's recommendations [5, 13]. Although

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

efforts have been made by governments of high TB/HIV burden countries and their partners to translate these recommendations into national policy and practice, implementation of both preventive therapies has been challenging and coverage has been low [2, 14, 15].

Objectives

The primary objectives of this review were to explore barriers to both preventive therapies reported across high TB/HIV burden countries (as per WHO [2]) and to generate explanatory knowledge of why their implementation has been so challenging. Additionally, this review aimed to compare both preventive therapies with respect to similarities and differences of barriers. A secondary objective was to identify strategies (facilitators) to improve the implementation of both preventive therapies. To identify relevant research, the broad question: “Which are the barriers to and facilitators for the implementation of preventive therapies (CPT, IPT) in countries with a high burden of HIV and TB?” was designed using FINER criteria [16] and the PICO framework: Population, Interest, Context (modified PICO) [17] (S1 Additional file). Barriers were defined as factors that limit, challenge or inhibit implementation, access, provision, delivery, or adherence to CPT or IPT. Facilitators were defined as factors that facilitate, support, encourage, or enable the implementation, access, provision, delivery, or adherence to CPT or IPT. In the published literature, the treatment of interest may be referred to as ‘preventive therapy’, ‘preventive treatment’, ‘prophylaxis’ or ‘prophylactic treatment’.

Methods

Protocol and registration

Following the Joanna Briggs Institute (JBI) methodology for mixed methods systematic review, we developed a protocol prior to undertaking the review [17, 18], which we registered and published in PROSPERO (CRD42019137778) (S2 Additional file). As outlined in section 8.5.1 of the JBI Reviewer’s Manual, we applied a convergent integrated

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

approach to synthesis and integration [18]. We followed PRISMA guidance and reported our findings, according to the PRISMA checklist (S3 Additional file) [19].

Eligibility criteria

Only peer-reviewed scientific papers meeting all of the following eligibility criteria were included: (1) papers reporting barriers and, or facilitators for either or both preventive therapies (CPT, IPT), sometimes in the literature also referred to as ‘preventive treatment’, ‘prophylaxis’, or ‘prophylactic treatment’. (2) Only studies conducted in high TB/HIV burden countries defined by WHO in the period 2016 to 2020 [2]; (3) published in English language; (4) until the 4th of September 2020 were eligible for this review. (5) Studied populations eligible were: (a) HIV patients or PLHIV. Although HIV-negative population groups may be eligible for IPT (e.g. household contacts of TB cases), HIV-negative population groups were not within the scope of this review. However, for CPT, HIV-exposed babies (HIV suspects) were eligible study populations, as well as patients co-infected with TB and HIV. Other studied populations eligible were (b) healthcare providers, also referred to as health professionals; (c) caregivers (i.e. parents or guardians of child patients involved in the preventive therapy collection or drug administration process); (d) any other stakeholder identified as influential in the overall implementation process of either IPT or CPT, and (e) countries defined by WHO as high TB/HIV burden countries [2]. Since this systematic review aims to analyse studies reporting primary data, we excluded editorial comments and systematic reviews. However, we screened reference lists of systematic reviews for original research eligible for this review. We included studies conducted in multi-sites or multiple countries only if barriers/ facilitators were separately analysed and reported per site or country. Because of the limited number of published qualitative studies on this topic, we included primary studies of any design (i.e. qualitative, quantitative, multimethod and mixed methods studies).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Information sources and search

In February 2018, we systematically searched the electronic databases MEDLINE®, Web of Science® and Scopus® for original articles using the search terms presented in (S4 Additional file). We repeated the search in September 2020 to identify additional literature published after February 2018 and updated our review [20]. The full electronic search strategy is available for each database search (S4 Additional file). We searched references of systematic reviews only if the systematic review was relevant to the study question.

Study selection

Following the search, PM collated and uploaded all identified citations into Endnote X9 reference management software, and removed all duplicates. We both independently screened and assessed all titles and abstracts against the predefined eligibility criteria for this review. Non-relevant studies and studies reporting from countries other than the thirty high TB/HIV burden countries were excluded during this initial title and abstract screening process. When the decision on exclusion was not clear, we included the study for full-text screening. PM retrieved the full-text of all potentially relevant studies. Eventually, we both independently assessed the full-text of the remaining studies against the eligibility criteria. Studies that did not meet all eligibility criteria were excluded, and reasons for exclusion were recorded. Studies that met all eligibility criteria were included. We compared our decision (i.e. inclusion/ exclusion and reason for exclusion) for each of the selected studies, discussed their full-text and resolved any disagreement concerning our decision through discussion.

Data collection process and data items

We developed a data extraction table which we initially tested on three studies to ensure that all relevant data items could be extracted. PM extracted the following data items from each included study: first author, year of publication, geographic origin (one or multiple

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

175 countries defined as high burden country for TB/ HIV), context (e.g. urban, rural), study type,
 176 study subject(s) of interest, sample size of study subjects for each data collection approach,
 177 study aim(s), data collection approach (e.g. interviews, record review), and findings related
 178 to the review question (i.e. barrier(s) and, or facilitator(s) for CPT, IPT, or both). LVL checked
 179 the extracted data items for accuracy and added or modified data items were necessary. We
 180 compared the data we individually extracted and resolved any disagreement through
 181 discussion.

182 Data transformation

183 As outlined in Section 8.5.1 of the JBI Reviewer's Manual, we extracted findings (barriers
 184 and facilitators) from quantitative, qualitative and mixed methods studies. Qualitative findings
 185 including the qualitative component of mixed methods studies were extracted as presented
 186 in the original research paper (e.g. themes, corresponding illustrations, paragraphs of textual
 187 description). We transformed quantitative findings, including the quantitative component of
 188 mixed methods studies, into textual description disregarding the effect size [18]. For
 189 example: "A quantitative study reported a twenty per cent decrease in cotrimoxazole stock-
 190 outs ($p < 0.05$) among health facilities that had employed trained pharmacy personnel,
 191 compared to health facilities without any trained pharmacy personnel." From this fictitious
 192 example, the following information would have been extracted: (1) Finding: Facilitator for
 193 CPT; (2) Description: employment of trained pharmacy personnel has shown to decrease
 194 stock-outs. Finally, we merged qualitative findings and transformed study findings together
 195 into one data set.

196 Risk of bias in individual studies

197 Due to the methodological diversity of the studies included in MMSR's, the selection
 198 of an appropriate tool that allows assessing the methodological quality of included studies is
 199 particularly challenging for this type of review. For the critical appraisal of methodological

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

quality (internal validity) of the included studies, we selected the “Mixed Methods Appraisal tool” (MMAT), version 2018 [21]. The MMAT is a critical appraisal tool designed for the appraisal process of mixed methods reviews because it specifically addresses items related to the various study designs being evaluated in a single tool [21]. Methodological quality criteria to be rated in the MMAT are specific for (a) qualitative research, (b) randomised controlled trials, (c) non-randomised studies, (d) quantitative descriptive studies, and (e) mixed methods studies (S5 Additional file). As reported by the Cochrane Qualitative and Implementation Methods Group, this tool has been used widely in systematic reviews and has the advantage of being able to assess interdependent qualitative and quantitative elements of mixed-methods research [22]. We independently assessed methodological quality based on the details published in the studies included in our review using the MMAT [21]. We resolved any disagreement in rating through discussion. To preserve the transparency of the risk of bias assessment, we documented all individual ratings for each study included in this review. For studies that failed to meet more than one quality criteria, we discussed whether to exclude the study. However, we also considered that our study's focus was on qualitative findings and on the generation of explanatory knowledge of why the implementation of both preventive therapies has been so challenging. Due to the risk of excluding insights relevant for a good understanding of the phenomenon under study, which may only become apparent at the point of synthesis, bias was toward inclusion [23, 24].

Qualitative synthesis

We applied framework synthesis, a highly transparent and deductive approach recommended for the synthesis of evidence on complex interventions [25]. This approach allows combining elements of critical realistic and subjective idealistic epistemology. We analysed our data set using MAXQDA Analytics Pro software (Release 18.1.1.), iteratively coding and sub-coding the extracted results. Both researchers individually defined, cross-

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

checked, discussed and refined the code system. We resolved disagreement through discussion.

Inspired by Getahun et al. (2010) [26], we applied a priori defined modified version of the WHO's Framework for action [27] to analyse and present barriers to preventive therapies. First, we assigned each extracted result (i.e. barrier) to one of the seven health system components based on the level at which they hindered implementation. Health system components include 'Patient & community', 'Health providers', 'Clinical information', 'Leadership & governance', 'Pharmaceutical management', 'Service delivery' and 'Financing'. We slightly modified three of the original component names and added the component "Patient & community" as the seventh component to the existing framework. Second, we thematically analysed each barrier considering its contextual description. Third, to summarise the comprehensive barrier descriptions, we applied metasummary. Metasummary is a quantitatively oriented aggregation of qualitative findings first proposed by Sandalowsky, Barroso and Voils (2007) [24, 28]. Mapping of key barriers across the seven health system components facilitated comparison of similarities and differences of barriers between both preventive therapies [25].

For facilitators, we applied 'the preventive therapy cascade' as framework for evidence synthesis. After familiarising ourselves with the extracted data set, reading and re-reading the identified facilitators and exploring underlying patterns, we found that facilitators generally aimed to enhance specific activities (e.g. providers' prescribing practices, patients' adherence) along a series of steps involved in the implementation of preventive therapies. Eventually, the preventive therapy cascade emerged as most relevant framework for the synthesis and presentation of our data, featuring each step along the preventive therapy cascade with all its bottlenecks. We assigned each extracted result to one or multiple steps along the cascade, followed by thematic analysis, inductively grouping facilitators into overarching themes [25].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Risk of bias across studies

Published studies are more likely to report statistically significant results compared to unpublished studies. Hence, publication bias compromises reviewers' ability to assemble a complete body of evidence that is not biased towards "positive findings". Although publication bias is primarily a concern for systematic reviews evaluating an intervention's effect, it is debatable whether the consequences of such bias is as potentially serious in qualitative evidence synthesis [29]. Dissemination bias (which encompasses publication bias) is gaining increasing attention in qualitative evidence synthesis. More research is required on how to assess dissemination bias in the context of qualitative evidence syntheses [30].

Additional analysis

Due to the complexities associated with findings derived from both streams of evidence and the impact of data transformation and integration on the grading process, an assessment of the certainty of the evidence is currently not recommended for MMSR's [18]. However, we analysed heterogeneity of the countries and the study subjects represented in this review and discussed potential limitations resulting from a heterogeneous representation of these variables.

Results

Study selection

The PRISMA Flow Diagram presents the number of papers included throughout the selection process, alongside with the reasons for exclusion (Fig 1).

Fig 1. PRISMA Flow Diagram.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Description of studies included in the systematic review

Forty studies were included for review, fourteen related to CPT [14, 15, 31-42] ; twenty-eight related to IPT [14, 38, 43-68], including two studies that reported findings on both preventive therapies [14, 38]. While facilitators were reported in all studies, barriers were not presented in three studies [32, 40, 41], all related to CPT. Comparing the year of the first publication included for both preventive therapies, we found that the first study included on IPT has been published fourteen years before the first study on CPT (1995, 2009) [38, 44]. All studies related to CPT were carried out in WHO African Region [14, 15, 31-42], while studies related to IPT also included WHO South East Asia Region [47, 61, 62], WHO Western Pacific Region [47] and WHO Region of the Americas [46, 47] (Fig 2).

Fig 2. Regional representation of countries included in this review. (A) High TB/HIV burden countries represented in studies reporting barriers or facilitators for cotrimoxazole preventive therapy (n= 7): Ghana, Malawi, South Africa, Tanzania, Uganda, Zimbabwe and Lesotho (published between 2009 and 2018). (B) High TB/HIV burden countries represented in studies on IPT (n= 22): Angola, Botswana, Brazil, China, DRC, Ethiopia, India, Indonesia, Kenya, Lesotho, Liberia, Malawi, Mozambique, Myanmar, Nigeria, South Africa, Swaziland, Tanzania, Thailand, Uganda, Zambia and Zimbabwe (published between 1995 and 2020). Source: Own visualization of review data: <https://www.amcharts.com/>.

Among the thirty countries defined by WHO as countries with a high burden of TB and HIV [2], we identified research from twenty-three countries (77%) reporting barriers or facilitators to either or both preventive therapies. Countries were disproportionally represented. The majority of studies were conducted in South Africa (n = 11) [37, 42, 47, 50-52, 54, 63-65, 67], Uganda (n = 9) [31-33, 38-40, 44, 56, 66], Tanzania (n = 5) [15, 35, 36, 47, 60], Kenya (n = 4) [45, 47, 49, 68], Zimbabwe (n = 3) [33, 34, 47], Ethiopia (n = 3) [47, 53, 58], and Nigeria (n = 3) [43, 47, 57]. Another fifteen countries were represented in only one or two studies. All studies, except three [33, 47, 49] based their findings on data collected in one single country. Half of the studies missed to mention the context where the study was carried out. Among the twenty studies that reported the context, ten were

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

conducted in urban areas [33, 35, 36, 41, 44, 45, 49, 58, 67, 68], eleven in rural areas [33, 38, 39, 42, 45, 49, 50, 55, 62, 63, 66] and six in intermediary areas [33, 38, 42, 44, 51, 65] (i.e. peri-urban, sub-urban, and semi-urban context). Some studies were conducted in multiple contexts.

Patients (n = 24) [31, 32, 35, 36, 38, 43, 44, 46, 48-52, 54, 55, 58-66], health providers (n = 14) [14, 15, 36, 38, 39, 45, 46, 51, 53, 54, 62, 63, 67, 68], and health facilities (n = 14) [15, 33, 36, 37, 39-42, 44, 45, 49, 56, 57, 67] were the study subjects of interest most frequently represented in this review, with at least one of the three study groups included in thirty-eight studies (95%). Few studies included other study subjects, explicitly caregivers [15, 34], community members [38], other stakeholders [14, 45, 46, 56], districts [38], and countries [47]. Table 1 shows the main characteristics of the studies included in this review. Additionally, we provided a more detailed presentation of study characteristics separately for studies on CPT and IPT (S6 Additional file).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

313 **Table 1. Main characteristics of the studies included in this review.**

First author [citation]	Year of publication	Country	Study type	Study subjects	Data collection approach	Treatment of interest
Adepoju [43]	2020	Nigeria	Retrospective cohort study	Patients	Record review	IPT
Aisu [44]	1995	Uganda	Operational Assessment	Patients, Facilities	Clinic attendance monitoring, Adherence (Pill count), Interviews, Review of key documents	IPT
Ansa [41]	2014	Ghana	Comparative research	Facilities	Record review	CPT
Catalani [45]	2014	Kenya	Mixed methods assessment	Providers, Other stakeholders, Facilities	Key informant interviews, Qualitative field notes of site observations, Interviewer-administered survey, In-depth interviews	IPT
Chan [33]	2014	Malawi, Uganda, Zimbabwe	Multi-country comparative study	Facilities	Interviewer administered survey, Record review	CPT
Chang [32]	2015	Uganda	Randomized trial	Patients	Survey-based assessment	CPT
Durovni [46]	2010	Brazil	Preliminary results of phased cluster randomized trial	Patients, Providers, Other stakeholders	Trial dataset record review, Interviews, Focus group discussion	IPT
Faust [47]	2020	Ethiopia, Nigeria, India, Angola, Brazil, China, DRC, Indonesia, Kenya, Lesotho, Liberia, Mozambique, Myanmar, South Africa, Tanzania, Thailand, Zambia, Zimbabwe	Survey	Countries	Survey (via email)	IPT
Gust [48]	2011	Botswana	Sub-study of the Botswana IPT prevention trial	Patients	Interviews, Focus group discussion, Interviewer-administered survey	IPT
Horwood [42]	2010	South Africa	Evaluation/ Cross-sectional descriptive study	Facilities	Record review, Survey-based interviews	CPT
Huerga [49]	2016	Kenya, Swaziland	Two prospective cohort studies	Patients/ Facilities	Record review (cohort study data, clinic registers), Interviews, Observation	IPT
Jacobson [50]	2017	South Africa	Qualitative study	Patients	Semi-structured interviews	IPT
Jarrett [51]	2019	South Africa	Multi-method assessment	Providers, Patients	In-depth interviews, Record review	IPT
Kamuhabwa [15]	2015	Tanzania	Retrospective descriptive study	Facilities, Caregivers, Providers	Record review, Interviewer-administered survey	CPT
Kamuhabwa [36]	2016	Tanzania	Descriptive cross-sectional study	Patients, Providers, Facilities	Record review, Semi-structured interviews, self-administered questionnaires, Focus group discussion, Facility assessment	CPT
Khan [52]	2014	South Africa	Diagnostic performance evaluation	Patients	TB screening questionnaire, Sputum specimens, Chest X-ray, Record review	IPT
Lai [53]	2019	Ethiopia	Cross-sectional study	Providers	Interviewer-administered questionnaires	IPT
Lester [54]	2010	South Africa	Qualitative methods study	Patients, Providers	In-depth interviews, Focus group discussion	IPT
Little [55]	2018	Malawi	Sub-study of the	Patients	Adherence (pills)	IPT

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

First author [citation]	Year of publication	Country	Study type	Study subjects	Data collection approach	Treatment of interest
			CHEPETS trial		dispensed at each visit), Interviewer-administered questionnaires	
Louwagie [37]	2012	South Africa	Historical cohort study	Facilities	Record review	CPT
Luyirika [40]	2013	Uganda	Retrospective case study	Facilities	Record review	CPT
McRobie [56]	2017	Uganda	Facility-level policy implementation assessment	Facilities, Other stake-holders	Key document review, structured health facility survey, Key informant interviews	IPT
Meribe [57]	2020	Nigeria	Assessment of a provider-focused intervention to increase IPT initiation and completion	Facilities	Review of routinely collected programme data, Health facility quality assessments	IPT
Mindachew [58]	2011	Ethiopia	Analytical cross-sectional study	Patients	Interviewer-administered structured questionnaires, Adherence (self-report)	IPT
Mugomeri [14]	2018	Lesotho	Qualitative study	Providers, Other stake-holders	Semi-structured interviews	CPT, IPT
Mugomeri [59]	2019	Lesotho	Retrospective cohort study	Patients	Record review	IPT
Munseri [60]	2008	Tanzania	Sub-study of the TB vaccine trial	Patients	Record review, Interviewer-administered questionnaires	IPT
Mwambete [35]	2013	Tanzania	Serial clinical and cross-sectional resistance study	Patients	Stool collection for resistance profiling, Adherence (self-report)	CPT
Naikoba [39]	2017	Uganda	Cluster-randomized trial	Providers, Facilities	Practical knowledge/competence assessment, Record review	CPT
Ngamvithayapong [61]	1997	Thailand	Prospective cohort study	Patients	Adherence (clinic attendance, pill count), Interviews, Focus group discussion	IPT
Okot-Chono [38]	2009	Uganda	Record review, qualitative study	Districts, Patients, Providers, Community members	Record review, Focus group discussion, Key informant interviews, In-depth interviews	CPT, IPT
Okwera [31]	2015	Uganda	Qualitative study	Patients	Focus group discussion	CPT
Reddy [62]	2020	India	Mixed-methods study	Patients, Providers	Review of routinely collected programme data, In-depth interviews	IPT
Rowe [63]	2005	South Africa	Record review, qualitative study	Patients, Providers	Record review, In-depth interviews	IPT
Selehelo [64]	2019	South Africa	Qualitative study	Patients	In-depth interviews	IPT
Sibanda [34]	2015	Zimbabwe	Qualitative study	Caregivers	In-depth interviews	CPT
Szakacs [65]	2006	South Africa	Adherence assessment, Cross-sectional study	Patients	Adherence (urine-metabolite testing, Interviewer-administered questionnaire)	IPT
Tram [66]	2019	Uganda	Cross-sectional study (sub-study of SEARCH HIV test and treat trial)	Patients	Record review, Interviewer-administered survey	IPT
Van Ginderdeuren [67]	2019	South Africa	Before-and-after study	Facilities, Providers	Record review, Structured questionnaire survey	IPT
Wambiya [68]	2018	Kenya	Qualitative study	Providers	In-depth interviews	IPT

Abbreviations: CPT- cotrimoxazole preventive therapy; IPT – isoniazid preventive therapy, Providers – Healthcare providers or healthcare workers

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

317 Risk of bias

318 We assessed the methodological quality of each study individually (S7 Additional
319 file). First, we identified the categories of study design using the MMAT algorithm and then
320 appraised each study against the corresponding methodological quality criteria [21]. Among
321 all studies reporting findings for CPT and IPT, more than half (57%, 50%) applied
322 quantitative methods [15, 32, 33, 35, 37, 39, 41-44, 47, 52, 53, 55, 57-61, 65-67], followed
323 by studies that applied a combination of methods (21%, 28%) [36, 38, 40, 45, 46, 48, 49, 51,
324 56, 62, 63] and those that applied qualitative methods (21%, 18%) [14, 31, 34, 50, 54, 64,
325 68], for CPT and IPT, respectively. Across all studies that combined quantitative and
326 qualitative methods, most (80%) presented no methodological attempt to integrate phases,
327 results, and data from both streams of evidence [36, 38, 40, 46, 48, 51, 56, 63]. Therefore,
328 nine studies were categorised as multimethod studies [36, 38, 40, 46, 48, 49, 51, 56, 63] and
329 two as mixed methods studies [45, 62]. According to the MMAT checklist, many included
330 studies (n = 29) have methodological limitations in at least one of the quality criteria
331 evaluated. Qualitative studies (including the qualitative component of mixed methods and
332 multimethod studies) frequently failed to address and justify the qualitative approach applied
333 (e.g. ethnography, phenomenology) [31, 34, 36, 38, 40, 46, 51, 54, 56, 62, 63]. Quantitative
334 non-randomized studies frequently failed to address whether the intervention or exposure
335 occurred during the study period as intended [41, 43, 58-60, 66]. Some studies also missed
336 to provide reasons why certain eligible individuals chose not to participate [55, 60, 65].
337 Similarly, the risk of non-response bias was frequently not addressed across quantitative
338 descriptive studies [15, 35, 42, 47, 57]. Overall, many studies' research question(s) lacked
339 clarity and focus [32, 35, 38, 45, 56, 59]. We identified seven studies with methodological
340 limitations in more than two of the quality criteria evaluated [35, 38, 40, 45, 46, 56, 62].
341 However, to gain a broader understanding of the barriers and facilitators to PT's, we did not
342 exclude any study from our analysis regardless of the methodological limitations.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Selective reporting of studies and findings in primary research may have introduced a risk of bias across studies. Similarly, publication bias may have led to a systematic distortion of our understanding of the phenomenon of interest, solely because specific findings are less easily accessible or available. Bias introduced through studies or findings that are not available (e.g. time-lag bias, truncation bias) could not be controlled. To address potential biases that result from studies being less easily accessible or available, we highlighted the absence of specific and relevant evidence in the limitation section of this review.

Barriers to preventive therapies

Patient and community related barriers

Adverse reactions, side effects or undesirable reactions were frequently assessed in the included studies [14, 15, 31, 34-36, 46, 48, 53, 58, 60-64, 66-68]. Many of these studies including two that based their findings on IPT trial data [46, 48] either found that both preventive therapies were generally well tolerated, that the majority of patients had not experienced any side effects, or both [15, 31, 35, 46, 48, 60, 63, 67]. However, we identified the following adverse reactions among a minority of patients.

Regarding CPT, few patients reported itches and headaches [35], nausea and vomiting [15, 35, 36], skin lesions or oral wounds [35], skin rashes [31, 35, 36], and hypersensitivity reactions [15]. Additionally, heartburn, throat dryness, dizziness, fatigue, appetite loss and numbness were reported by few HIV-positive adults [35]. In rare cases, severe cutaneous reactions or burning sensations (e.g. Stevens-Johnson syndrome) required therapy interruption [31, 36]. In this case, some received dapsone as an alternative therapy for the prevention of opportunistic infections [31].

Regarding IPT, few patients reported headaches [46], arthralgia [46, 48], pruritus [46, 64], dizziness or fatigue [48, 62, 64], gastrointestinal disturbances [46, 62, 64], nausea or appetite loss [48, 60, 62], vomiting [62, 64], weight loss [48] and darker skin complexion [64].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

The most serious, very rarely reported adverse reactions to INH were seizures, psychiatric symptoms [48, 64], (peripheral) neuropathy [60, 62] and mild to moderate hepatotoxicity [46, 60]. Very few patients experienced adverse reactions that required therapy interruption [48, 60, 63]. After stopping IPT, liver function abnormalities resolved [60].

Co-administration of other drugs was believed to have contributed to adverse reactions [35, 36, 48]. The simultaneous administration of ART, TB treatment and other drugs (e.g. to treat hypertension, diabetes, asthma) was common among PLHIV [35, 36, 48, 64]. One patient reacted to concurrent CTZ and INH, two weeks after initiating ART [14]. Concurrent use of CTZ and nevirapine may have contributed to rash and leukopenia [36]. Besides, pyridoxine shortages and patients' poor nutritional status were believed to have contributed to INH-associated neuropathies [62].

Our review revealed that side effects influenced patients' and health providers' views, attitudes and practices regarding the use and prescription of preventive therapies. Some had heard about side effects and feared experiencing such reactions in the future [31, 34]. Three studies suggested that fear of potential side effects alone contributed to patients' non-adherence to IPT [58, 60, 68]. However, seven papers also reported actual or perceived side effects as the reason for patient-initiated non-completion or lacking adherence to IPT [58, 60-62, 66, 68] and CPT [36]. Tram and colleagues (2019) found that patients who reported side effects, and those who believed INH was dangerous for their health had lower odds of completing IPT [66]. Eventually, patients who stopped taking IPT may have discouraged others from initiating the preventive therapy [68]. For IPT, side effects and contraindications were also acknowledged by health providers [53, 62, 67]. For example, health providers interviewed in rural India believed that side effects were an important reason for non-completion of IPT [62]. Although health providers believed that IPT was important for PLHIV [53], due to side effects and contraindications (e.g. active liver disease, history of adverse reactions), sometimes the therapy was not prescribed [53, 67].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Instead of discontinuing CPT, some patients independently reduced the prescribed doses as a measure to manage side effects [15, 35, 36]. Parents reported reducing their infants' doses of CTZ if they were unwell or perceived side effects [15]. Similarly, HIV-positive pregnant women reported skipping doses of CTZ for the same reason or taking CTZ at night to cope with perceived side effects [36].

Lacking financial and organisational feasibility frequently emerged as barrier theme [15, 34, 38, 44, 46, 48, 50, 54, 58, 60-63, 65]. Evidence synthesis revealed that long distance to the clinic [44, 60], lacking transport [15, 44], and the with transportation associated costs [44, 46, 48, 50, 54, 63] routinely comprised an obstacle for patients to access therapy and care. Women and adolescents were reported to lack control over economic resources, leaving the decision to attend the clinic with their parents or husbands [63]. Jacobson et al. (2017) [50] argued that a major barrier to IPT had been patients entering HIV care. The researchers suggested that once linked to care (i.e. adherent to ART), the marginal cost for patients to take IPT was low in the South African study setting [50]. Our review found that frequent stock-outs at public health facilities caused therapy interruptions among patients who could not afford to buy INH or CTZ at the community pharmacy [15, 34, 38, 65]. Research from Uganda and Brazil suggested that TB screening incurred additional costs for patients, including fees for chest radiology, transport for three consecutive smear checks [46], as well as consultation fees [38]. HIV-positive clinic attendees in South Africa frequently reported hunger and lack of food security. Lacking food appeared to be a barrier to IPT because patients believed they could not take the therapy without food intake [63]. Health providers in Karnataka, India, listed 'lack of social support and access to social protection schemes' as a reason for patients' non-completion of IPT [62]. In terms of organisational feasibility, studies from Botswana and South Africa showed that patients were facing competing priorities, with the need to choose between spending a full day waiting at the clinic, dedicating the time to their work [48, 50, 54] or addressing other family members' needs [50, 63]. Studies from Ethiopia, Botswana, Uganda and Thailand

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

showed that patients did not access treatment or care, when they relocated [48], moved far away [44] or were seeking work in other provinces [35, 50, 58, 61]. Parents and caregivers reported lack of a refrigerator at home as challenge for storing paediatric formulations of CPT [15].

Knowledge gaps and misperceptions regarding both preventive therapies were barriers for patients' retention in care, therapy adherence and completion [15, 31, 38, 44, 48, 50, 51, 54, 61-64, 67, 68]. Patients in Uganda thought that CTZ is an analgesic drug, that concurrent use of CTZ and ART, or TB treatment is contraindicated, and that CTZ was a treatment for HIV-positive patients [31]. In Tanzania, parents and caregivers reported difficulties in understanding how to use CPT. They particularly struggled to prepare the CTZ suspension for their children using crushed tablets when the paediatric formulation was unavailable [15]. Patients in Thailand thought that INH was prescribed to reduce HIV blood concentration or prevent AIDS-related complications [61]. Patients in South Africa believed that INH would alleviate symptoms, leaving asymptomatic patients unconvinced [50]. Three studies reported that HIV-positive adults were not aware of the desired benefit of IPT in preventing TB [50, 54, 61], and some patients had never heard of IPT [61]. Not knowing the benefit, seemed acceptable for some patients, as shown in three studies, which revealed that patients took IPT without understanding its purpose or duration [50, 61, 64]. However, most studies suggested that low patient knowledge about IPT is rather harmful for its implementation [44, 48, 50, 61, 63]. Knowledge gaps can create wrong assumptions, mislead patients from the appropriate medical advice, or promote seeking information from other sources [61]. Five studies reported insufficient patient information was a reason for missing pills, therapy interruptions, or non-compliance to clinic appointments among PLHIV [44, 48, 50, 61, 63]. Qualitative research conducted in South Africa revealed that some patients interrupted therapy, thinking they no longer needed IPT when INH refills were accidentally omitted [50]. This patient belief illustrates that knowledge gaps among PLHIV also undermine patients' potential to generate demand for IPT [62]. Patients in Uganda and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

South Africa felt better and did not understand the need to return to the clinic, or to take IPT when they did not have TB, suggesting they lacked understanding of the concept of prevention [44, 51, 63]. Health providers interviewed in Kenya, South Africa and India also acknowledged this problem [51, 62, 68]; some patients refused to take ‘TB medicine’ [INH] without having TB [51, 68]. Others did not value the preventive effect of IPT because of the low perceived risk of TB and lack of symptoms [62]. Health providers reported that information materials were lacking or inadequate to educate PLHIV, suggesting there was a lack of social campaigns, and consensus regarding patient education activities [62, 68].

Patients’ lacking motivation [15, 44] was identified for both preventive therapies alongside with a number of explanations [15, 31, 34, 38, 44, 48, 54, 58, 62-64, 68]. Patients reported they struggled with the need for too many clinic visits, on the one hand, due to a lack of same-day services [38], on the other hand, due to the long waiting time prior to receiving services [38], as well as the long preventive therapy duration [58, 68]. Patients reported they were too busy to take IPT [44, 63] and also struggled with the daily pill burden [31, 48, 54, 62, 64, 68], which was exacerbated through co-medication [54, 64]. Patients revealed they received ART, medications for hypertension and diabetes, or asthma in addition to IPT [64]. Pill burden affected patients adherence, providers believed [62, 68]. Some patients feared adding to the pill burden [62]; others completely declined to take IPT due to the high number of pills prescribed to PLHIV [68]. Studies from Uganda and South Africa reported that patients presumed side effects [44], found IPT unnecessary [63] or were just not interested in taking IPT [44]. Research from Zimbabwe revealed that one mother felt let down by pharmaceutical interventions and stopped giving CPT after her baby tested HIV-positive [34].

Forgetfulness has been frequently reported as a reason for patients’ non-adherence to preventive therapies [35, 48, 58, 65].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Patients' HIV denial, religion and competing medicinal approaches impeded patients acceptability of preventive therapies [34, 36, 44, 48, 61, 63, 66]. Patients' denial of HIV was a barrier to patients' retention in care [61], and consequently, their preventive therapy uptake. Mothers who tested HIV-positive in Zimbabwe associated their diagnosis with impending death and reported that they preferred to ignore HIV and not give CPT to their babies when they felt depressed [34]. Non-compliant adult patients interviewed in Uganda and Thailand were not accepting their HIV status and thus, never returned to the clinic, or only months later [44, 61]. Research from Uganda suggested that after receiving their test result patients were still in the process of coping with their HIV diagnosis [44]. Religion and competing medicinal approaches were barriers identified on the sub-Saharan continent. Three studies suggested an influence of religion as an explanation for HIV denial [36, 48, 63]. Interviews with HIV-positive pregnant women in Tanzania revealed that people diagnosed with HIV were encouraged to pray that God will cure their infection, while born-again Christians were advised to stop taking CTZ [36]. Self-reported reasons for non-adherence and loss-to-follow up in the Botswana IPT trial also included religious beliefs [48]. In South Africa, a study participant who interrupted IPT reported that members of the church could not combine clinic medication with church tea. Similarly, people believed it was prohibited to take clinic medication with traditional medicines [63]. According to Rowe et al. (2005), HIV was perceived as incurable by western medicine, while traditional healers were perceived as able to cure HIV, suggesting two competing medicinal approaches [63]. Survey-based research conducted in Uganda found that among non-completers of IPT, some patients took traditional medicines 'to prevent becoming sick with TB' [66].

Stigma and fear of rejection or discrimination remains a barrier for HIV care and consequently for the implementation of both preventive therapies [34, 36, 38, 44, 48, 50, 60, 61, 63, 65, 66]. Cotrimoxazole and IPT were linked to HIV [36, 60, 63, 66], which although a common infection in the countries included in this review, was frequently associated with stigma and fear of rejection [34, 60, 63] or discrimination [48, 60, 63]. Studies found that

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

women feared separation from their spouses and families because of their diagnosis [34, 60]. Although mostly reported by women, in-depth interviews with HIV-positive mothers in Zimbabwe, suggested that men also feared separation from their wives when testing HIV-positive [34]. HIV-positive people were laughed at or ridiculed, suggesting a lack of understanding of HIV within the community [34]. Among men, HIV was perceived as emasculating [34]. These HIV-positive patients' experiences explain their frequently cited unwillingness to disclose their HIV status [34, 36, 50, 60, 61, 63]. One study reported that a woman disguised her HIV medication in a container for headache medication [50]. With the intention to keep their diagnosis secret, it has been difficult for women to take CPT at their crowded homes or administer it to their babies [34, 36]. Study participants in northern Thailand did not allow nurses to visit their homes because they wanted to keep their HIV status confidential [61].

The fact that patients feel the need to keep their HIV status confidential is a concern because it is likely to contribute to the non-completion of preventive therapy. According to Tram and colleagues (2019) [66], 'not talking to friends or family about IPT' was associated with non-completion of IPT' while 'feeling comfortable taking IPT in front of a friend' was an independent predictor for IPT completion among HIV-positive study participants in rural Uganda. Lacking privacy and confidentiality at the health facility made it difficult for women to hide their diagnosis [44]. People attending the overcrowded health facility took the risk of being seen by their spouses and the community when collecting CTZ prescription refills [34] or sitting in the open waiting area [38]. Fear of stigma within the household, caused challenges to therapy adherence [58], whereas perceived at the health facility level, hindered patients' retention in care [60].

Influence of relatives and friends may be an important factor for the implementation of both preventive therapies [31, 34, 36, 44, 48, 60, 62, 63]. Although social and family support seemed to positively influence some patients' therapy adherence [63],

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

compliance with the prescribed therapy regimen was at threat when patients lacked this support [34, 44, 60, 63, 66]. Sometimes, relatives and friends adversely influenced patients' compliance with their clinic appointments, retention in care, therapy adherence or completion. Some patients felt discouraged by their relatives, who disapproved or sabotaged their treatment adherence [31, 44, 48, 60]. Interviews with HIV-positive adults in Uganda and Tanzania revealed that some had been discouraged by their spouse or relatives to take IPT [44, 60]. Similarly, HIV-positive adults in Uganda were advised by their relatives to discontinue CPT [31]. Interviews with HIV-positive mothers in Zimbabwe suggested that some husbands opposed CPT. They refused to accept their wife's HIV status and treatment, as well as the administration of CPT for their baby [34]. Research from Botswana reported stolen pills, 'the boyfriend threw out the pills', or 'the sister flushed them down the toilet', as reasons for trial participants discontinuation of IPT [48]. Some wives reported their husbands stole their CTZ to take themselves [34]. Health providers in Tanzania reported that HIV-positive pregnant women sometimes discarded CTZ, or shared it with their family members [36].

Socio-demographic, lifestyle and clinical factors appeared to influence peoples' use of IPT (i.e. their chances of initiating, receiving, completing or adhering to IPT) [14, 46, 48, 55, 58-60, 62, 66, 68]. Studies suggested that people's age (being younger) [48, 55, 59, 62, 66], low literacy or educational level [60, 62], their lifestyles [46], including drinking alcohol [48, 62], negatively influenced patients' use of IPT. With respect to sex, we identified contrasting findings; five studies suggested that being female was positively associated with the use of IPT [48, 55, 59, 61, 62], while one study from Tanzania suggested vice versa [60]. Although there was some consensus that younger age was positively associated with the use of IPT [48, 55, 59, 62, 66], some subgroups lagged behind. In particular, children (and adolescents) had a lower probability of initiating (or receiving) IPT compared to their adult counterparts [14, 59, 62]. Pregnant women (unaware of their HIV status) attending antenatal care services as late as 36 or 38 weeks of pregnancy [14, 48], people aged over 65 [62] and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

spouses of PLHIV also lagged behind [14, 62]. A higher education level seemed to improve the chances of IPT initiation [62] and completion [60]. A mixed-methods study from India found that compared to those who were illiterate, patients with formal education had a higher chance of IPT initiation [62]. The authors argued higher IPT completion rates among participants with education above the secondary level could have been due to patients' better understanding and comprehension of instructions [60]. Health providers interviewed in Kenyan cities thought non-adherence was more likely across patients with a poor immunological and clinical state and patients on second-line ART [68]. Similarly, results of a retrospective cohort study carried out in Lesotho suggests that patients with WHO clinical stage 4 were more likely to interrupt IPT than those with clinical stage 1, 2, or 3 [59]. Those bedridden and with a poor clinical state may be interrupting IPT due to difficulties in reaching the distant hospital [59].

Concern about the efficacy of CPT resulted from the steady evolution of antibiotic-resistant bacteria. Research from Dar es Salaam, Tanzania, attempted to investigate the incidence of faecal *E. coli* resistance to CTZ among HIV patients through in-vitro resistance testing and found considerably high antibacterial resistance. The authors concluded resistance concerns and suggested reconsidering the use of CPT in Tanzania [35]. Our review also identified factors that may have contributed to the evolution of CTZ-resistant bacteria. Factors presented by Okwera et al. include poor adherence to CPT and doctors' loose prescription practices [31]. Besides, the availability of antibiotics without prescription (in pharmacies, parks, or bus stations) may have promoted resistance to CTZ through irrational use and self-medication [31, 35]. We did not identify resistance concerns or scepticism about the continuous efficacy of CPT among health providers.

Health provider related barriers

Shortage of health providers working at public health facilities emerged as a barrier for both preventive therapies [14, 36, 38, 43, 45, 46, 51, 56, 62, 64, 67, 68]. However, except

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

from one study that referred to CPT [36], all other studies reported staff shortages as an obstacle for the implementation of IPT [14, 38, 43, 45, 46, 51, 56, 62, 64, 67, 68]. Shortage of health providers was found in a range of countries including South Africa [51, 64, 67], Uganda [38, 56], Kenya [45, 68], Tanzania [36], Nigeria [43], Lesotho [14], Brazil [46], and India [62]. Regarding CPT, Kamuhabwa et al. (2016) [36] reported a shortage of pharmaceutical personnel at the twenty-six antenatal clinics included in their study in Tanzania. Regarding IPT, three studies from Uganda and Kenya explicitly stated health provider shortages with few providers trained in IPT [68] or co-management of TB-HIV [38, 56], and altogether too few health professionals to implement HIV policies [56]. A disproportional provider-patient ratio was reported, suggesting the number of health providers did not allow the additional tasks required to deliver IPT [62, 64, 68]. Studies from Brazil and Kenya, aimed at exploring doctors attitudes to IPT, described doctors' pressure to see as many patients as possible (i.e. twenty to forty patients per provider before taking lunch), thus indirectly reported provider shortages [45, 46]. Interviews with HIV and TB doctors regarding their work, motivation and capacity to implement IPT in HIV clinics in Brazil, showed that they were too busy, tense and solitary [46]. Although doctors interviewed in Kenya believed in the importance of IPT for PLHIV, they found it difficult to manage TB priorities among many other priorities [45]. Two studies from Uganda further advised that working conditions (i.e. low salaries, heavy workloads) and missing incentives (i.e. career development prospects) were demotivating for health providers, leading to high staff attrition and consequently loss of knowledge [38, 56]. Similarly, research from South Africa reported high staff turnover, which seemed to exacerbate the human resources challenges [67]. To assess IPT completion rates among HIV-patients and determine predictive factors for IPT completion, Adepoju and colleagues (2020) [43] carried out a retrospective cohort study that included HIV-patients from six governmental hospitals in Nigeria. The study reported human resources challenges in many hospitals and service delivery units. Similarly, a Ministry of

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

605 Health key informant said that staff shortage was a major challenge for implementing IPT in
606 Lesotho [14].

607 **Knowledge and training gaps** regarding both preventive therapies were identified among
608 health providers, limiting their ability to make appropriate therapy decisions [14, 36, 38, 39,
609 42, 44-46, 51, 54, 62, 68].

610 Regarding CPT, knowledge gaps existed among low and mid-level health providers
611 regarding the co-management of patients with HIV and TB [38, 39], CPT for malaria
612 prevention among HIV-positive pregnant women [36, 42], and CPT for babies born to HIV-
613 positive mothers [42]. Kamuhabwa et al. (2016) [36] applied multiple methods to assess CPT
614 implementation among HIV-infected pregnant women in malaria-endemic Tanzania after the
615 national policy had been changed from recommending sulfadoxine-pyrimethamine (SP)
616 intermittent preventive therapy to recommending CPT for malaria prevention in this patient
617 population. Although health providers perceived the new policy on CPT has been clearly
618 written and was understandable, they still did not have sufficient knowledge about the
619 inclusion criteria (HIV serostatus confirmed, time of initiation, no history of allergic reactions
620 caused by sulfur-containing drugs), and exclusion criteria (skin rashes, Stevens-Johnson
621 syndrome). The authors concluded that inadequate training was among the factors driving
622 poor implementation of CPT [36]. Task shifting is an important strategy to strengthen health
623 provider capacity; however, studies from Tanzania and South Africa have shown that lower
624 cadre required training to pursue their roles [36, 42]. Lay counsellors in South Africa
625 admitted they were undertaking tasks outside their scope when providing CTZ to babies [42],
626 while nurses in Tanzania dispensed medicines, including CTZ, without pharmacy training
627 [36].

628 Regarding IPT, knowledge gaps existed among HIV providers with various levels of
629 education, including doctors. Our evidence synthesis suggested that providers were
630 comfortable managing PLHIV [46], but lacked knowledge about TB [44, 46] and TB

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

631 prevention [14, 45, 46, 51, 54, 62, 68]. Interviews carried out with doctors specialized in HIV
 632 in Brazil reported knowing the ART recommendations, but lacking knowledge about TB
 633 prevention and co-management of (HIV and) TB [46]. One of the ten patients interviewed as
 634 part of a multi-method assessment carried out in South Africa described being incorrectly
 635 denied an IPT prescription; according to the interviewee, the nurse refused to prescribe IPT
 636 because the patient did not have TB, suggesting knowledge gaps among nurses in the study
 637 setting [51]. Other knowledge gaps identified were related to the target groups for IPT [14,
 638 62], IPT duration [51, 68] and the assessment of IPT eligibility [14, 45, 46, 51, 62]. Two
 639 studies revealed a lack of familiarity with IPT prescription requirements for children [14, 62]
 640 and pregnant women [62]. One study found that of the twenty-two providers involved in IPT
 641 prescription, not many knew that specific tablets were available for children (paediatric
 642 dosage) [62]. Lacking clarity was identified about the role of chest x-ray when determining
 643 IPT eligibility [45] and regarding the initiation of IPT without placing a TST [51]. Nurses
 644 pointed out that although the national guidelines instruct them to prescribe IPT even if the
 645 TST is out of stock, the guidelines state that a TST must be placed one month after IPT
 646 initiation. Not knowing what to do if TST remained out of stock after IPT initiation, sometimes
 647 prevented them from prescribing altogether [51]. Additionally, nurses were unsure how IPT
 648 duration varied by patient age, TST result, pregnancy and ART status [51] and about the
 649 period after which IPT should be repeated [14]. Research from South Africa revealed that
 650 doctors lacked knowledge about the IPT guideline and were concerned about the need to
 651 screen for and rule out active TB before initiating IPT [54]. Some health providers had
 652 theoretical knowledge about the IPT recommendations [45, 51], but lacked experience or
 653 familiarity in applying these guidelines in a clinical setting [45, 51, 54]. One nurse reported
 654 she had never used a TST on a patient in her clinic and was unsure whether she could read
 655 the result [51]. Lack of knowledge and familiarity with IPT among providers was explained by
 656 inadequate staff education [14, 38, 45, 62, 68], and minimal follow-up supervision after
 657 training [38]. Criticism was raised regarding the training modules provided to health

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

providers because they lacked content on TB-HIV collaborative activities [38], or included limited or no specific training on IPT [68]. Consequently, providers felt inadequately equipped to handle emerging challenges associated with IPT implementation [68]. Research conducted in Lesotho by Mugomeri et al. (2018) [14], suggested that inadequate training has been the main reason behind delayed IPT initiation in the study setting.

Negative attitudes, concerns and fears among health providers impeded the delivery of IPT [14, 44, 45, 53, 54, 62, 64, 67, 68]. Our review revealed that health providers often had a negative or sceptical attitude toward IPT, for which we found several explanations [45, 51, 54, 62, 67, 68]. Providers perceived patients' irregular clinic attendance, non-adherence to IPT and high loss to follow-up as demotivating and discouraging for IPT initiation. Counselling patients about IPT and encouraging them to adhere to preventive therapy was perceived as difficult and time-consuming [67]. During in-depth interviews, nurses working in HIV care in South Africa expressed that patients misunderstood or were unwilling to cooperate with an IPT prescription. In the absence of external oversight (e.g. clinical mentorship), nurses would lose their motivation to prescribe IPT interviews revealed [51]. Other factors that have discouraged providers from prescribing IPT include discomfort with the long duration of IPT [68], the increasing workload [45, 68], managing IPT among other priorities, and the influence of fellow health providers [68]. Two studies reported that negative perceptions or doubts about IPT among some health providers affected the perception and delivery of IPT by their fellow providers [54, 68].

Although evidence strongly recommends concomitant use of IPT with ART, research from Lesotho suggests a general perception that HIV patients who are on ART for a long time have a low-risk of developing TB. For this reason, providers mostly prescribed IPT to patients newly diagnosed with HIV [14]. We also identified contrasting perceptions about the effectiveness of IPT. Research from Lesotho stated that health providers perceived IPT was effectively reducing TB disease among patients with HIV [14]. Meanwhile, a study from

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

684 South Africa reported health providers were unconvinced about the benefits of IPT [54].
 685 Concerning was that consequently, health providers omitted to prescribe IPT in the South
 686 African setting. Qualitative research carried out by Lester and colleagues (2010) [54] aimed
 687 to explore patients' and providers' attitudes toward IPT. The study found that none of the
 688 twenty HIV-patients interviewed had heard of IPT and doctors were either unaware of the
 689 efficacy of IPT in preventing TB or believed the evidence was equivocal. Clinic staff and
 690 doctors admitted that IPT was not part of routine practice (such as CPT); the authors
 691 concluded that in this setting barriers to IPT were predominantly derived from health
 692 providers [54].

693 Health providers' concerns and fears were related to active TB [14, 44, 64, 67, 68], antibiotic
 694 resistance [45, 54, 64, 68] and side effects [14, 53, 68]. In the first place, health providers
 695 were concerned about their ability to exclude active TB based on TB symptom screening.
 696 Providers who worked in a setting where no TST was available believed that applying the
 697 screening algorithm alone was insufficient to rule out TB [67, 68]. Atypical clinical
 698 presentations complicated TB screening of patients coinfecting with TB-HIV [54], and
 699 occasionally, HIV-patients developed TB disease during [44, 64] or after the course of IPT
 700 [14, 44, 64]. Drug resistance was another concern of health providers which led to
 701 scepticism about IPT [45, 54, 68]. Bacterial resistance to INH was believed to result from
 702 providers' failure to rule out TB [64], periodic and long-term drug stock-outs [45], patients'
 703 non-adherence to IPT [68] and the use of IPT in settings with a high prevalence of multi-drug
 704 and extremely drug-resistant TB [54]. First, failure to rule out TB was revealed by Selehelo,
 705 Makhado and Madiba (2020) who reported that health providers sometimes prescribed IPT
 706 without symptom screening [64]. Their qualitative study applied in-depth interviews with HIV-
 707 patients to explore their experiences regarding IPT provision and derive strategies to
 708 improve IPT uptake in community health centres in South Africa. Patients interviewed
 709 reported that symptom screening for active TB was not done before the provision of IPT and
 710 that they developed TB while on IPT, regardless of reporting symptoms to the nurses [64].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Second, health providers working in selected clinics in Kenya reported they were concerned about contributing to drug resistance by exposing patients to IPT when INH stock-outs did not permit therapy completion. If they were not confident all their eligible patients had 9-months IPT supply providers preferred not to initiate IPT [45]. Third, health providers interviewed in urban HIV clinics in Kenya expressed their concern that patients non-adherence would lead to the development of resistant, multi-drug resistant or extensively drug-resistant TB [68]. Fourth, health providers interviewed in South Africa expressed such fear of inducing multi-drug resistance through INH monotherapy that some suggested starting empirical courses of full treatment for TB. Providers believed a combination of drugs was safer and offered greater benefit than INH monotherapy [54]. Eventually, some providers feared that INH could induce side effects [14, 53, 68]. Overall, the fears and concerns described made health providers feel uncomfortable or unwilling to prescribe IPT.

Provider-patient communication emerged as a barrier to the implementation of IPT. Our review revealed that patients were often afraid to speak to health providers about IPT, suggesting ineffective provider communication and a lack of trust in the health provider-patient relationship [50, 51, 58]. Jacobson and colleagues (2017) [50] explored patients' reasons for default from IPT through individual interviews. IPT defaulters stated that they avoided reporting side effects, questioning missing medications, or requesting to re-start IPT after treatment lapses, due to their fear of nurses scolding [50]. Research from Ethiopia found that patients lacked advice from doctors, feared side effects and stigma [58]. The authors concluded lack of provider-patient communication contributed to patients non-adherence to IPT [58]. Similarly, HIV-patients interviewed in South Africa revealed that they felt intimidated during their conversation with nurses; nearly half of them reported that nurses were sometimes rude and that this discouraged them to ask about IPT [51].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

735 **Clinical information related barriers**

736 **Inaccurate recording and lacking integration of health records emerged as a**
 737 barrier for both preventive therapies [14, 36-38, 42, 45, 51, 63, 67]. Although poor recording
 738 of clinical information on patients' records was frequently reported [14, 37, 38, 42, 45, 67],
 739 our review revealed that incomplete records did not necessarily imply that services have not
 740 been provided [14, 37, 42, 45]. Horwood et al. (2010) interviewed HIV-positive mothers in
 741 South Africa, regarding the health services and interventions their babies had received, and
 742 compared this information with data recorded on the post-natal ward- and child health
 743 records [42]. According to the mothers, significantly more babies had received CPT,
 744 compared to what has been recorded on their health records [42]. Similarly, Lougwagie et al.
 745 (2012) [37] reviewed altogether over two-thousand patient records from separate and semi-
 746 integrated health facilities. Their study showed that CPT was less well recorded than
 747 counselling and HIV testing, raising the question whether this was due to poor recording or
 748 poor provision of the preventive therapy [37]. Van Ginderdeuren and colleagues (2019) [67]
 749 obtained a similar pattern of results for IPT. Their record review showed a discrepancy
 750 between what has been recorded by health providers in IPT registers and what patients had
 751 received according to pharmacy records. The authors concluded underreporting of IPT in
 752 routine IPT registers [67]. In line with this finding, Mugomeri et al. (2018) [14] suggested
 753 underreporting of monthly statistics through the paper-based record system.

754 However, we identified weaknesses related to the health information systems
 755 available to record patient data, contributing to inaccurate recording practices. First, health
 756 information systems in many TB/ HIV high burden countries were paper-based or relied on a
 757 mix of paper-based and electronic records [14, 45]. Research from Uganda described
 758 recording tools were poorly designed and unpractical; HIV registers lacked data entry
 759 sections regarding TB-HIV collaborative services, and TB information were only recorded on
 760 patients' chronic care cards [38]. Similarly, Jarrett et al. (2019) [51] reported that patient

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

charts were disorganised and lacked a specific log for IPT registration, making it challenging to track each patient's progress toward IPT completion. Most nurses discontinued IPT to avoid the possibility of prescribing IPT past the intended duration, a study from South Africa revealed [51]. Providers relied on a patchwork of documents completed by various team members in a Kenyan study setting where patients did not see the same provider during each visit [45]. The study reported that health providers frequently suffered from missing patient data. In case patient data were missing, patient self-report was used to determine the steps of TB diagnosis and IPT eligibility assessment previously completed. Doctors reported they trusted patient recall over electronic medical record (EMR) data when patient information conflicted [45].

Our review revealed that lacking integration of patient data recorded from different service units bears two risks. First, documentation of patient data in separate patient files (e.g. HIV registers, patients' chronic care card, laboratory-, pharmacy records) affected service delivery efficiency by multiplying the time spent for document retrieval, data entry, and in some cases the provision of services that had already been provided [38, 45]. Second, in the context of TB-HIV co-infection, poor recording, communication and lacking service integration [36, 63] may lead to preventable drug interactions or adverse reactions. A study from Tanzania reported that eight HIV-positive pregnant women were co-administered both SP and CPT for malaria prevention, which is contraindicated because of increased risk of severe cutaneous reactions [36]. Research from South Africa reported that four patients whose clinical records suggested they were not eligible for IPT, had started the course [63].

Ineffective monitoring, evaluation and surveillance emerged as a second barrier related to clinical information [14, 38, 56, 67]. Both concepts, monitoring and evaluation (M&E) and surveillance require collecting data, that are analysed, and finally transformed into strategic information that governments and leaders use to make informed decisions. We identified weaknesses of the health information system and found that patient data recorded

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

at the health facility level were commonly inaccurate or lost [14, 45]. The detection and notification of health events (surveillance) and reporting of routine programme data (M&E) consequently leaked in its foundation.

In 2009, research from Uganda reported that no tools existed for routine recording and reporting of TB-HIV surveillance data that permitted informing planning processes [38]. Eight years later, McRobbie et al. (2017) [56] reported that there were still no regional or national information systems in place, that allowed the integration and submission of health facility data in Uganda. Different views about obstacles for M&E in Lesotho were particularly well described by Mugomeri et al. (2018) [14]. Through interviews with key informants, the qualitative study found that major barriers to the implementation of IPT included ineffective health information systems [14]. The representative of the WHO country office in Lesotho warned that the IPT indicator system was paper-based and that data reported by health facilities were inaccurate. One health provider acknowledged that the total number of patients enrolled in IPT was unknown due to a shortage of paper registers [14]. The provider added that monthly reports were sent to the MoH for congregate analysis, but feedback was rarely received at the health facility level. The investigators confronted the responsible ministry of health (MoH) representative who explained that it was not feasible to frequently assess the effectiveness of their programmes and that their primary goal was to increase IPT uptake. Providers were concerned that INH could induce side effects; some believed that poor M&E resulted in the late detection of these undesirable reactions [14]. A partner organization representative acknowledged the need for more resources, including stationary and patient registers, and noted that failure to monitor patient referral, additionally confounded monthly statistics [14]. A study from South Africa showed that IPT indicator data were not comparable due to inconsistent denominators across health facilities. Some facilities routinely collected data to measure IPT uptake among all PLHIV and others used HIV-patients newly enrolled in HIV care as denominator [67]. Weaknesses identified by Okot-Chono et al. (2009) [38] included that the existing supervisory visits carried out by

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

national and district officers for monitoring of the TB-HIV collaborative activities were infrequent and had not been performed jointly by the TB and HIV programmes.

Pharmaceutical management related barriers

Drug stock-outs or shortages were common for both preventive therapies [14, 15, 33, 34, 36, 38, 45, 50, 51, 56-58, 62, 64, 65, 67, 68]. Except from one study that reported stock-outs in India [62], all other studies reported stock issues in countries located in sub-Saharan Africa. African countries included Kenya [45, 68], South Africa [50, 51, 64, 65, 67], Uganda [38, 56], Tanzania [15, 36], Zimbabwe [34], Nigeria [57], and Lesotho [14].

Inconsistent drug supply, periodic and long-term stock-outs, or shortages of CTZ [14, 15, 33, 34, 36, 38] and INH [14, 45, 50, 51, 56, 57, 62, 64, 65, 67, 68] were obtained from record reviews, reported by patients, health providers, representatives of MoH or partner organizations. It may be noteworthy, that stock-outs were also reported for dapsone, an alternative drug to CTZ [14] and pyridoxine, a drug prescribed to prevent peripheral neuropathy caused by INH [14, 62]. Our review revealed consequences of and reasons for the inconsistent availability of CTZ and INH.

Stock-outs of INH hindered therapy initiation [45, 56, 62], therapy adherence [64, 65] and completion [62]. Interviews with doctors in Kenya showed that providers remained hesitant to initiate IPT due to frequent pharmacy shortages [45]. Providers in Kenya perceived stock-outs of INH and other supplies related to IPT as a major impediment to effective implementation and acceptance of the therapy. Some providers felt the poor supply of INH showed a lack of support for the IPT programme among policy-makers and management. This, in turn, negatively affected their perception, morale and delivery of IPT [68]. HIV patients interviewed in South Africa, reported medication stock-outs as the reason for defaulting or not adhering to IPT [50, 65]. In-depth interviews with HIV-patients in South Africa revealed that patients perceived the occasional unavailability of INH as inconvenient

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

and frustrating because it increased clinic visits and may lead to non-adherence [64]. One study suggested that the location from which PLHIV collected their drug supply may have predicted adherence to IPT, as peripheral pharmacies ran out of INH more frequently than hospital pharmacies [65].

For CTZ, the included evidence suggested that drug shortages led to irregular uptake of CPT [38], dose alterations among infants [15, 34], and patients skipping scheduled clinic visits [36]. Stock-outs of CTZ at health facilities and HIV clinics were reported as the reason why many children had missed one or more doses of CPT [14] and why only a few TB/HIV co-infected patients received CPT regularly [38]. Studies from Tanzania and Zimbabwe found that frequent shortages of the paediatric formulation at health facilities caused challenges to caregivers and providers [15, 34]. In Tanzania, parents had difficulties understanding how to crush tablets and prepare suspensions for their infants [15]. Lack of CTZ at the health facilities was suggested as a reason for pregnant women skipping visits scheduled at the antenatal clinics [36].

Among explanations to why health facilities and pharmacies frequently ran out of CTZ, we found an increasing number of HIV patients [38], inaccurate recording [36], challenges with quantification and forecasting of the prescribed preventive therapy [36, 38]. At the health facility level, we identified the late submission of health facility requisitions [38] or ordering of drug quantities that did not cover the facility demand [36]. Outside the health facility level, we found district-wide stock-outs of INH [51] and scarcity of CTZ at the medical stores department or government supplier side [15]. A lack of support from policymakers, programme management [14] or district health departments to adequately supply the lower level units with medicines was also believed to facilitate stock-outs [38, 68]. A district health officer interviewed in Uganda reported that it was not surprising that CTZ was not available at the health facilities. Health offices failed to support lower-level health providers with correctly quantifying drugs in stock and calculate drug consumption [38]. Ineffective supply

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

chain management [13, 35, 63, 65] and logistical challenges [58] provided alternative explanations for frequent stock-outs. Finally, an uncoordinated implementation of IPT shown by Meribe et al. (2020) [57] also led to long-term INH stock-outs. Their study reported a strong focus on IPT at the beginning of the implementation process in Nigeria, which led to the utilization of all stock at most sites, followed by national level stock-outs that lasted from December 2018 to April 2019 [57].

Lack of pharmaceutical personnel emerged for both preventive therapies [36, 56]. Studies reported that sites in Uganda lacked a dedicated logistics manager [56] and that health facilities lacked pharmacy personnel in Tanzania, where nurses without pharmaceutical training dispensed medicines [36]. **Lack of written instructions** was reported by Kamuhabwa et al. [36] referring to missing documented strategies for ensuring the availability of CTZ at the health facilities on one hand, and missing written instructions clarifying how medicines should be administered by patients at home on the other hand. The authors suggested the need to provide patients with a list of known potential adverse reactions, including those that require to stop taking the therapy [36].

Service delivery related barriers

Sub-optimal service delivery emerged as a critical barrier for the implementation of both preventive therapies. We identified examples of sub-optimal service delivery in fourteen studies that reported from a large range of countries with a high burden of TB and HIV [15, 34, 37, 38, 42-44, 46, 50, 51, 56, 62, 64, 68]. These examples primarily showed that service delivery was time-consuming, the patient was not put at the centre of care and that health services delivery was inefficient.

Service lapses, limited working days, and doctors' limited working hours have been reported at public health facilities [44, 50]. A study from Uganda found that the AIDS information Centre was closed when patients returned the first time after testing HIV-

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

positive; they never returned thereafter [44]. Studies reported that patients faced long queues, spending hours waiting before receiving services or their medications [34, 38, 50, 64]. Jacobson et al. (2017) [50] reported that HIV patients endured long queues to collect their medicines, often skipping meals and taking medications on an empty stomach [50]. Dispense of IPT and ART in separate lines [50] and the lacking synchronization of IPT with other HIV clinic appointments [43] added to patients' waiting time and clinic visits. A qualitative study explored women's ability to maintain their babies on CPT. The study found that mothers typically had to dedicate the entire day to one clinic visit, which they found difficult, considering they also had to attend the clinic for their own HIV care [34]. Due to lack of same-day services, one family had to spend multiple days at the clinic for HIV care [34, 38], providing a possible explanation why only a few HIV-positive mothers in South Africa reported attending regular follow-up for their own care [34], and why patients felt discouraged. Overall, services delivery did not appear patient-friendly and routinely tested patients' willingness and ability to receive HIV care [44]. Other examples of sub-optimal service delivery showed weaknesses in the quality of healthcare provided.

Patient information, including tolerance to preventive therapy, side effects, drug interactions, and therapy adherence, were frequently missing on patient records [14, 64, 66]. Some HIV-patients reported that their test results got lost at the health facility [50]. Interviews revealed that HIV-positive mothers had received insufficient quantities of CTZ, lasting for forty days, while their next clinic appointment was two months away [34]. Often, there was no follow-up of HIV-patients who missed clinic appointments [15].

Among the potential underlying causes of sub-optimal service delivery, the disproportional provider-patient ratio was the most prominent. Human resource constraints presented a critical operational challenge to HIV services delivery [56, 62, 64]. As a result of MoH funding constraints (and differing donor priorities), there were too few providers available to provide necessary services [56]. It may be noteworthy that since the scale-up of HIV testing and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

ART followed by the universal treatment policy released in 2015, there has been an ever-increasing number of PLHIV requiring continuous treatment and care. So far, the majority of HIV services have been delivered at the health facility level, resulting in organisational and operational challenges to handle the heavy patient load [15, 38, 40, 56, 62, 64]. For IPT, the high patient load was believed to prevent nurses from screening every patient for IPT eligibility [51]. Among other factors, IPT service delivery was believed to be greatly affected by lack of integration between HIV and TB services [46], the inconsistent INH drug supply [51, 62, 68] and inadequate records for IPT registration [51].

Inadequate facility infrastructure emerged as barrier theme for both preventive therapies [15, 38, 56]. Health facilities in Tanzania lacked weighing scales to determine infants' weight for CTZ doses calculation. Thus, providers based the doses on age rather than weight, unable to ensure infants received the correct amount of preventive therapy [15]. Facility infrastructure has been reported as inadequate to ensure patients' privacy and confidentiality; lacking counselling rooms and inadequate space to implement the HIV policies was reported [38, 56]. Research from Uganda suggested that an outside waiting area for HIV services attendees may raise suspicion among husbands seeing their wives there seated, suspecting that she may have contracted HIV [38].

Poor integration of preventive therapy-related services was another important cross-cutting barrier theme [14, 33, 36, 38, 42, 46, 50, 54, 56, 68] that arose from the segregated delivery of health services in many high TB/HIV burden countries. Studies showed that preventive therapies were frequently not part of the services provided at the health facility [33, 42, 56]. Not all primary care facilities in Malawi and Uganda offered CPT for patients with HIV on-site [33]. Only half of the immunization clinics in a South African study setting provided CPT for HIV-exposed babies [42]. None of the twenty-four health facilities, included in a study carried out in Uganda, offered IPT as service for patients with HIV [56]. Likewise, research showed that additional testing services required before initiating IPT were also

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

frequently not available on-site [54, 68], which meant that for receiving preventive therapies, patients had to attend other health facilities as well.

Overall, preventive therapy was poorly integrated with other speciality services [36, 38, 46, 50, 54, 68], often requiring patient referral between health facilities and incurring additional patient costs [38, 68]. However, inter-clinic referral was reported to be weak [14, 38], added to patients' costs [68] and challenged service quality [54]. In Kenya's capital HIV clinics, most clinical examinations required before IPT initiation were carried out in separate departments [68]. According to a study that was carried out in South Africa, only one of ten clinics had onsite chest radiography, while none could test sputum on-site. Investigations for TB performed off-site lacked coordination between TB and HIV shown in lost specimen and laboratories not communicating TB test results with HIV sites. Lacking coordination between TB and HIV sites was believed to hinder patients' initiation of IPT [54]. Poor inter-clinic referral and separate clinic days for TB and HIV services were reported in Uganda, demonstrating poor integration of IPT with HIV care [38]. Interviews with key informants in Lesotho suggested that confirmation of patients' arrival at the referred centre was often lacking [14]. Wambiya and colleagues (2018) [68] interviewed eighteen health providers in urban Kenya to explore factors that influenced providers' acceptability of IPT. The study reported that most clinical examinations were conducted in separate departments at additional costs. Health providers urged that all testing services should be provided at the same site. Costs incurred by additional exams should be subsidised to increase IPT uptake, providers argued [68]. The need to refer patients to another facility for preventive therapy, not only added to patients' waiting time and transport costs, it has shown to carry service delivery related risks, such as dual administration of intermittent treatment for malaria prevention in HIV-positive pregnant women. A study identified patients in Tanzania who received both, SP at the antenatal care unit, and CPT at the Prevention of Mother To Child Transmission (PMTCT) unit [36]. Research from Uganda reported that few TB patients were tested for HIV, not identifying co-infected patients eligible for CPT [38]. In South Africa,

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

efforts have been made to integrate IPT-related services with ART services at the same location. However, interviews with HIV-patients from four primary care health facilities and one district hospital revealed that IPT and ART were dispensed in different queues and that most facilities had not fully integrated TB and HIV services on-site [50].

Patient loss to follow-up was identified for both preventive therapies [42, 48, 55, 56, 62, 63, 67], referring to patients not linked to care (after HIV diagnosis) and those who stopped attending clinic appointments. Mc Robie and colleagues (2017) [56] argued that recent efforts in Uganda had focused on HIV testing and immediate ART provision without strengthening health facility infrastructure and human resources accordingly to allow the implementation of the complete set of HIV care policies. Consequently, systems failed to maintain patients in care downstream in the care cascade, the authors concluded [56]. Besides difficulties to retain patients in care, engaging those reluctant to present for HIV services (i.e. testing, care and support) from the beginning, also remained a challenge for HIV service delivery [63].

A sub-study of the Botswana IPT trial explored self-reported reasons for trial participants' loss to follow-up (LTFU) following IPT initiation. Reasons included patients' financial and organisational feasibility to attend the clinic appointments, lacking motivation or social support. Stigma, relocation, religious beliefs, and pregnancy also comprised reasons for patients to stop preventive therapy, while some believed they had completed the study [48]. We identified another example showing patients' loss to follow-up due to lack of linkage to care, which can turn into a lost opportunity to provide CPT, as shown in a study from South Africa. Coverage of PMTCT interventions was high during pregnancy and delivery, but mothers and HIV-exposed infants were poorly linked to follow-up care after the baby was born. The provision of CPT was also poorly recorded on the child health records. Follow-up care (e.g. CPT and HIV testing of the new-born) therefore depended on the mother reminding the health provider that their baby has been HIV-exposed. Less than half of the

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

eligible babies had a PCR test and initiated CPT at their first visit to the immunization clinic [42]. Research suggests that patients' non-completion of IPT was frequently associated with failure to return to the clinic for follow-up of IPT [55, 62]. Recent efforts have focused on assigning health providers responsible for contacting these patients via telephone or in-person. However, providers perceived that following-up of these patients was difficult and time-consuming [67].

Ruling out TB disease has been reported as a major barrier to implementing [14, 38, 45-47, 49-54, 62, 64, 67, 68]. Due to the need to rule out TB disease before therapy initiation and during the course of IPT, delivery of IPT has been perceived as difficult [53]. Since 2011, WHO recommends using a simple algorithm to identify PLHIV unlikely to have active TB, no longer requiring other tests in countries where other tests are not available [13]. However, some countries continued using other recommended tools to determine patients' eligibility for IPT. According to a recent email survey [47], three different TB screening tools were used for PLHIV in high TB/HIV burden countries. Besides symptom-based TB screening (Kenya, Lesotho, Liberia, Myanmar, Nigeria, South Africa, Tanzania), tuberculin skin tests (Brazil, Ethiopia, Indonesia and Thailand) and interferon-gamma release assays (Ethiopia) have been used. Several countries reported combining screening tools (Brazil, Ethiopia, Indonesia, Kenya and Thailand). For example, Brazil reported using a combination of tuberculin skin tests (TST) and chest radiography, while Kenya reported a combination of symptom-based screening and radiography [47]. Evidence synthesis revealed several limitations for each screening tool.

First, weaknesses of TST were frequently associated with the tuberculin (purified protein derivate) required to carry out the test. We identified shortage of purified protein derivate (PPD), delayed or insufficient supply from the manufacturers [47], challenges of ensuring the quality of PPD [47, 49], as well as the limited utility of TST in settings where BCG vaccination continued [47]. One study aimed to assess the acceptability and

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

operational feasibility of TST in urban Kenya and rural Swaziland [49]. The study revealed that some health providers initially confused tuberculin with BCG vaccine. In both settings, some patients received an inappropriate amount (half-dose) of tuberculin injection. In rural Swaziland, cold chain monitoring issues were experienced [49]. Besides, the need for a second visit for TST reading was a major concern among patients and providers, implying additional time and transport costs [49, 67]. A questionnaire survey designed to identify barriers to IPT was administered to health providers in South Africa [67]. Survey findings showed that health providers had no time to perform TST; they found the TST reading time consuming and struggled to motivate patients to return for the reading [67]. Research from Brazil reported an alarmingly long time between the first clinic visit to IPT initiation. The time delay was explained by the fact that TST was not routinely offered in all clinics on all days and the chain of processes involved in TST. Once an asymptomatic patient received a positive TST result, chest radiography was required to rule out TB, for which the patient received a prescription. The patient then needed to schedule an imaging appointment before returning to the clinic to present the result to the doctor. Adding to the delays involved in the process of TST testing, patients may not have felt the urgency to quickly return to the clinic because they did not feel sick, the authors argued [46]. A review of patient records from five primary care health facilities revealed that only the facility that opted against TST reported a significant increase in IPT uptake [67]. Overall, the reported findings suggest that TST may have contributed to the low uptake of IPT [46, 47, 67]. At the time of our review, TST had been removed from most high burden countries' IPT policies. However, some countries, including Brazil, continued to apply TST as a necessary screening component [47]. Proponents of TST argued that providing IPT only for those with latent TB infection (after careful exclusion of active TB) would avoid unnecessarily treating a significant number of patients that do not stand to benefit [49].

Second, more recently developed interferon-gamma release assays (IGRAs) address important limitations of TST. Patients are only required to visit the clinic once for blood

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

collection and the result is available within one day. Additionally, prior BCG vaccination does not cause a false-positive IGRA test result. However, due to a lack of budget, lab infrastructure and trained personnel, and insufficient capacity for specimen transport, these relatively expensive tests have hardly been used in TB/HIV high burden countries [47].

Third, symptom-based TB screening refers to a simple algorithm applied prior to initiating IPT and at every follow-up visit, thus allowing health providers to interrupt preventive therapy in case a patient develops symptoms of TB. Those who do not report any symptoms of current cough, fever, weight loss, or night sweats are unlikely to have active TB. If no contraindications to IPT exist, these patients should be offered preventive therapy [13]. Although symptom-based screening has significantly advanced IPT uptake in low-resource settings [53], we identified challenges associated with this approach.

Challenges included doubts about the reliability of TB symptom screening among patients with HIV and TB-HIV, lacking provider capacity to routinely screen TB symptoms, and service delivery inefficiencies. Solely based on TB symptom screening, health providers found it difficult to rule out active TB [53] or decide whether a patient had active or latent TB [68]. Some providers believed that using the screening algorithm alone was insufficient to rule out TB [54, 67, 68]. Opponents of symptom-based screening argued that atypical clinical presentations complicated TB screening of patients coinfecting with TB-HIV who frequently suffered from extrapulmonary TB [54]. Khan et al. (2014) carried out a diagnostic performance evaluation among HIV patients in South Africa [52]. Study findings suggested that symptom-based screening was very sensitive and diagnostically useful among patients not on ART, however, less reliable among patients on ART [52]. The high patient load was believed to prevent providers from screening every HIV-patient for IPT eligibility [38, 51]. During interviews conducted in South Africa, nurses repeatedly stated that staff shortages and the large patient burden prevented them from screening every HIV patient [51]. Research revealed possible consequences of providers' lacking capacity to screen patients

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

for TB. Health providers either lose their motivation to prescribe IPT [51] or continue prescribing IPT without TB symptom screening [64, 67]. The latter was shown by Selehelo et al. (2019) [64]. The authors reported providers were prescribing IPT without screening for TB symptoms, which meant risking a delay of TB treatment and favouring the emergence of drug resistance [64]. We identified service delivery issues with symptom-based screening that delayed IPT initiation. Research from Lesotho [14] suggested that ineffective TB screening was due to an inefficient service delivery system. Delays in IPT initiation have been reported for patients with presumptive TB, indicating it took much time until TB was ruled out. The study also found that IPT was mainly initiated among patients newly diagnosed with HIV, while IPT uptake among patients enrolled on ART before IPT was launched in 2011 lagged behind [14]. Health providers interviewed in India reported that proxy attendance delayed IPT initiation. In the mainly rural study setting, patients often send their caregivers or other attenders to collect their ART refill, making it impossible for providers to assess patients' eligibility for IPT [62]. In Kenya, a combination of TB symptom screening and obligatory chest radiography was applied to determine HIV-patients' IPT eligibility [45, 47]. Doctors reported they were unsure about the steps to take to determine IPT eligibility. However, doubts were mostly related to the role of chest x-rays, when and if it should be ordered and how to read the radiographs [45]. Irrespective of the screening tool applied in each country, suspects of TB required additional investigation.

Investigation of TB suspects is a crucial requirement for all patients with a positive TB screening result [13]. For those who developed TB during the course of IPT, additionally, drug susceptibility testing should be performed [52]. However, we identified several challenges associated with evaluating patients with presumptive and confirmed TB [14, 38, 45, 49, 52, 54, 64, 67]. Diagnostic equipment needed to investigate TB included chest radiography [54], laboratory equipped for the analysis of sputum samples [45] and the identification of resistant TB strains [52]. However, the capacity to diagnose TB was limited in high TB/HIV burden countries, where most health facilities could not diagnose TB on-site

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

[52, 54]. Although the more accurate GeneXpert® test allows rapid diagnosis and identification of patients with drug-resistant TB, this expensive molecular test technology was often only available at centralised sites, reserved for a subset of complex cases [14, 45]. Besides, our review revealed knowledge gaps among health providers related to co-management of TB-HIV [38] and their diagnostic competences [38, 45]. In Kenya, doctors specialised in HIV reported they were unsure how to read a chest radiograph [45]. Providers in Uganda reported struggling with the assessment of smear-negative and extra-pulmonary TB [38]. Most concerning was the study finding that only a minority of PLHIV with self-reported symptoms were investigated for TB [49, 67], causing TB treatment delays [64] or resulting in too many patients denied for IPT [49].

Health system financing related barriers

Health system funding issues were identified for both preventive therapies [14, 15, 47, 56]. Many high TB/HIV burden countries historically depended on funding for HIV and TB from international donors and governments. Many will continue to require donor backing to improve the provision of a comprehensive care package to PLHIV [56].

Lacking funds to purchase essential medicines (as which CTZ and INH are classified), has been reported in a Tanzanian study setting [15]. The quantitative descriptive study involved questionnaire-based interviews with health providers, who suggested lack of funds to purchase essential medicines at the health facility level had been an attributing factor for drug scarcity at public hospitals [15]. Similarly, qualitative research from Lesotho reported that among the main challenges for implementing IPT were interrupted supply chains caused by insufficient health system funding [14]. Through interviews with MoH key informants, health providers and representatives of partner organisations, the study found that additional resources were needed to sustain a seamless supply of drugs and reagents. A health provider reported that health facilities frequently ran out of CTZ, pyridoxine, and dapsone, among other drugs. Ministry of health officials expressed the need for health system funding

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

to be increased to improve the sustainability of HIV/ TB programmes, including IPT [14]. A recent email survey carried out by Faust et al. (2020) [47] aimed to identify challenges experienced in countries with a high burden of TB regarding the implementation of latent TB infection policies. Respondents from six high TB/HIV burden countries (i.e. Ethiopia, Liberia, Nigeria, South Africa, Tanzania, Zimbabwe) reported that guidelines existed, but due to financial barriers guidelines were not fully implemented [47].

Vertical funding emerged as barrier theme for both preventive therapies [14, 38, 56], referring to a stand-alone programme approach (e.g. HIV programme, TB programme) used in many resource-constrained countries for health system funding, typically associated with vertical governance and health service delivery. However, health system strengthening and the integrated provision of interventions that go beyond a single disease programme are not characteristic for vertical funding. Both preventive therapies are good examples for interventions that require some degree of collaboration between disease programmes (i.e. HIV, TB, PMTCT, child health) to ensure their successful implementation. Lacking funds for implementing TB/HIV collaborative activities in Uganda was reported on a national TB/HIV programme level and district level [38, 56]. Policymakers reported international donor dependency of the HIV programme [56]. Implementers and researchers interviewed about HIV policy implementation in Uganda reported misalignment of goals between the government and donors in determining priorities, suggesting lacking donor support for health systems strengthening and prevention activities [56]. Donors were considered to focus more on the provision of ART [56], while human resources constraints presented a critical operational challenge for providing HIV services, including IPT [14, 56]. However, funding of human resources primarily rested with the individual Ministry of Health [14, 56].

Leadership & governance related barriers

Issues regarding policies and guidelines emerged for both preventive therapies [14, 15, 38, 47, 51, 54, 67, 68]; however, were most commonly reported for IPT. A recent

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

survey [47] suggested that guidelines on latent TB infection (LTBI) did not exist in several high TB/HIV high burden countries (Angola, China, DRC, India, Indonesia, Kenya, Myanmar) [47]. Barriers to guideline implementation reported among these countries included prioritization of active TB over LTBI management (Angola, China, DRC, India, Kenya), financial barriers to programme implementation (Angola, DRC, Kenya), lack of programme staff (DRC) as well as guideline development still in progress (India, Indonesia, Kenya, Myanmar). The study suggested that in China, PLHIV were not targeted for LTBI treatment. However, the evidence relied not only on National TB programme staff but also on researchers and health officials. Findings, therefore, reflect the respondents' current knowledge and not necessarily the official situation in their respective countries [47].

Preventive therapy guidelines were not always accessible [15, 38] and understandable for health providers [14, 15, 38, 51, 68]. Health providers in Tanzania reported no up-to-date guidelines were available at the health facility, hindering effective implementation of CPT for children born to HIV-positive mothers [15]. In Uganda, district officers had received policy guidelines on TB/HIV collaborative services but had not disseminated the documents to providers and communities [38]. In Kenya, South Africa and Lesotho, national guidelines for IPT were described as unclear [14, 68], ambiguous, confusing, and incomplete [51]. Lesotho's guideline was reported to lack clarity about the duration after which IPT should be repeated. Health providers noted that they were left with too much flexibility regarding the timing of IPT initiation. Some providers initiated ART before IPT to allow unmasking side effects of ART and ensure patients are stable. Others prescribed IPT only two weeks after ART initiation. This flexibility in the guidelines was believed to have contributed to the poor implementation of IPT [14]. Research from Kenya suggested that lacking clarity of IPT guidelines meant that providers struggled to implement IPT effectively. According to health providers from three HIV clinics in Nairobi, Kenya, particularly unclear were eligibility criteria and the duration of IPT, as well as how to decide whether a patient had active or latent TB [68]. Lacking clarity might have contributed to

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

health providers' low fidelity to the IPT guideline in South Africa [54, 67]. Van Ginderdeuren et al. (2019) [67] reported that across selected primary care health facilities, TST was not implemented as intended, symptomatic patients were not investigated for TB, and IPT initiation rate was generally low. Others have shown that, only in one out of ten sites included in their study, health providers prescribed according to the existing policy guideline. Providers seemed to lack clarity regarding the eligibility criteria for IPT. For example, some thought that IPT was indicated for patients with a CD4 count below 200 cells per microlitre, or reserved for patients on ART [54].

Lacking leadership and coordination emerged for both preventive therapies [14, 38, 42, 46, 50, 51, 68]. Both interventions require some degree of collaboration between disease programmes (i.e. HIV, TB, PMTCT, maternal and child health) to ensure their successful implementation. However, weak leadership and coordination at the strategic and operational level have been reported as a major challenge for TB/HIV collaborative activities [38, 46, 68]. Studies showed that TB and HIV services' responsibilities remained fragmented [46, 50] with lacking clarity concerning roles and responsibilities for collaborative service delivery at the health facility level [38, 42]. Research from Uganda found that it was not clear in the Ugandan study setting whether the responsibility for coordination belonged to TB or HIV health providers. With the exception of two health facilities, no coordination meetings had been held between the two programmes [38]. Mugomeri et al. (2018) [14] suggested that lack of leadership was among the major barriers to scaling-up IPT for PLHIV in Lesotho. Research carried out in two KwaZulu-Natal districts showed that PMTCT services were poorly integrated with maternal and child health services. Interviews with nurses and lay counsellors revealed a lack of clarity regarding their roles and responsibilities in the provision of CPT for HIV exposed babies [42].

Lacking top-down policy support and management issues emerged as barriers for both preventive therapies [38, 50, 51, 68]. On an institutional and policy level, we

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

identified a lack of commitment, support and oversight as barriers to implementing IPT policies and collaborative TB/HIV activities. Providers interviewed in Kenya felt demotivated by the limited commitment at the policy level in ensuring effective implementation and streamlining of the IPT programme [68]. After investigating patients' reasons for defaulting IPT, Jacobson et al. (2017) [50] concluded that long queues, drug stock-outs, and a lack of service integration require attention on an institutional and policy level. At the health facility level, 'no-one was overseeing' the implementation of TB/HIV collaborative services, participants of a study conducted in Uganda reported. Inadequate joint supervision may lead to providers' poor performance, the authors suggested [38]. Similarly, in South Africa, nurses admitted that in the absence of external oversight, they would lose their motivation to prescribe IPT [51]. The multimethod study carried out by Jarett et al. (2019) [51] involved interviews with health providers after they had received a nurse-centred intervention. The intervention was designed to promote two target behaviours: checking IPT-eligibility for all PLHIV and prescribing IPT to this target population. The authors concluded that without adequate oversight, complicated guidelines would continue to hinder the implementation of IPT.

Inadequate planning was identified as a barrier to the implementation of IPT and TB-HIV collaborative activities [14, 38]. Inadequate national planning was reported as an important barrier to IPT implementation in Lesotho, key informants said. Representatives of partner organizations reported that IPT was affected by lack of foresight at the planning stage and poor capacity to solve problems that arise [14]. Multimethod research from Uganda revealed that out of five districts implementing TB-HIV collaborative activities, only one had incorporated collaborative activities into its district work plan. The remaining four districts had separate HIV and TB plans that excluded TB-HIV joint activities. Another barrier to TB-HIV collaborative activities reported by the authors was that patients and communities were not involved in the planning process [38].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Lacking stakeholder engagement emerged as a barrier theme for both preventive therapies, suggesting that community consultation and engagement of implementers and the population targeted for preventive therapies were insufficient, which may have hindered the scale-up of preventive therapies [14, 38, 68]. According to research from Uganda, community-related activities were planned without community involvement. Additionally, the study reported a lack of information flow from health facilities to the communities concerning the TB and TB-HIV services available [38]. The limited engagement of health providers in the development of the IPT guideline provided one explanation for their low acceptability of IPT in Kenya [68]. Health providers interviewed in Nairobi's selected HIV clinics reported they were told: "Here are the guidelines to be followed!". Providers felt they should have been involved in the process of guideline development [68]. Similarly, lacking engagement of the people responsible for implementing IPT (i.e. health providers) was reported to inhibit IPT uptake in Lesotho [14].

Metasummary

We summarised the identified barrier themes in tables and compared both preventive therapies with respect to similarities and differences of barriers (S8 Additional file). Overall, thirty-two barrier themes emerged from the comprehensive barrier description of which the majority were cross-cutting barrier themes (n = 25). We also identified seven intervention-specific themes.

Barrier themes specific to CPT (n = 2) were 'concerns about the efficacy of CPT' in areas of high bacterial resistance [31, 35] and a 'lack of written instructions' (i.e. procedures to ensure the availability of CTZ and patient information) [36]. Barrier themes specifically identified for IPT (n = 5) include 'patients' socio-demographic, lifestyle and clinical factors' [14, 46, 48, 55, 59-62, 66, 68], 'providers' attitudes, beliefs & fears to induce INH resistance' [14, 44, 45, 51, 53, 54, 62, 64, 67, 68] and challenges related to 'provider-patient communication' [50, 51, 58]. Additionally, we identified issues with 'ruling out TB disease'

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1258 [14, 38, 45-47, 49-54, 62, 64, 67, 68] and ‘the investigation of TB suspects’ as intervention-
1259 specific barriers for IPT.

1260 After carefully grouping each barrier to the health system component from which it
1261 arose, we compared both preventive therapies with respect to similarities and differences of
1262 health system components most frequently associated with barriers. We found that barriers
1263 to both preventive treatments were most frequently related to ‘health service delivery’ and
1264 ‘patients & their community’. For IPT, health provider related barriers seemed to play an
1265 additional important role, third most frequently referred to. In contrast, barriers to CPT, were
1266 third most frequently related to ‘pharmaceutical management’. ‘Financing’ was among the
1267 health system components least frequently associated with barriers to either of the
1268 preventive therapies. We applied an innovative mapping technique to summarise the
1269 comprehensive barrier information. The resulting metasummary graphics illustrate all
1270 identified weaknesses (i.e. barrier themes) within each of the seven health system
1271 components, together with the number of papers that contributed information to each barrier
1272 theme. Therefore, mapping allows visual comparison of barrier themes identified for CPT
1273 (Fig 3) and IPT (Fig 4).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1274 **Fig 3. Metasummary: Barriers to cotrimoxazole preventive therapy for people living with HIV.** The graphic presents all main barrier themes identified in countries with a
1275 high burden of tuberculosis and HIV, assigned to the health system component from which the barrier theme arose, considering a seven component health system framework
1276 (modification of the WHO Framework for Action, 2010). Barrier themes identified in more than or equal to ten papers are presented with an exclamation mark. Numbers in
1277 brackets display the number of supporting papers. Total number of peer-reviewed papers included with barriers to cotrimoxazole in this review (N= 11).

1278 **Fig 4. Metasummary: Barriers to isoniazid preventive therapy for people living with HIV.** The graphic presents all main barrier themes identified in countries with a high
1279 burden of tuberculosis and HIV, assigned to the health system component from which the barrier theme arose, considering a seven component health system framework
1280 (modification of the WHO Framework for Action, 2010). Barrier themes identified in more than or equal to ten papers are presented with an exclamation mark. Numbers in
1281 brackets display the number of supporting papers. Total number of peer-reviewed papers included with barriers to isoniazid in this review (N= 28).

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Facilitators for the implementation of preventive therapies

We identified a set of strategies for enhancing the health facility-based implementation of preventive therapies for PLHIV. We presented our findings, according to the preventive therapy cascade - a coding framework that we developed a priori (Fig 5).

Fig 5. The preventive therapy cascade.

TB - tuberculosis; HIV - human immunodeficiency virus; PLHIV- people living with HIV; IPT- isoniazid preventive therapy; CPT - cotrimoxazole preventive therapy.

The preventive therapy cascade outlines the steps that PLHIV repeatedly go through from having access to appropriate healthcare to completing preventive therapy. We developed this conceptual framework to promote stakeholder discussion about the 'weak spots' within the cascade in their specific setting. We listed the identified facilitators for the implementation of both preventive therapies accordingly. Therefore, this approach allows stakeholders (1) to select steps within the cascade that require attention, (2) to rapidly screen potential strategies that address these 'weak spots' within the cascade and (3) collaboratively choose a combination of strategies that are most appropriate in their specific context. For example, strategies to enhance patients' adherence to PT's are presented in section F6, shown in Fig 5. and Table 2.

Table 2. List of facilitators for the implementation of CPT and IPT.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F1	<p>Access: Strategies for health system strengthening, improving access to and quality of health care</p> <p><u>Leadership & governance</u></p> <ul style="list-style-type: none"> • Increase the number of health care facilities (especially in rural areas) [48, 60]. • Decentralised provision of preventive therapies (PT's) and related services: <ul style="list-style-type: none"> - at health centres rather than just hospitals [53, 62], at the community level (e.g. mobile radiology units) [45]. - home-based care for selected patient groups (i.e. HIV+ pregnant women) [32, 36]. • Raising community knowledge & awareness about HIV & PT's (via education campaigns, health talks, initiatives [34, 64, 68]: <ul style="list-style-type: none"> - to reduce stigma, peoples' fears and misperceptions (e.g. reduce the 'emasculating' stigma of HIV through education messages that emphasise how treatment after testing HIV+ can help a man achieve his 'manly' roles by maintaining his health, allowing him to 'provide for the family') [34, 64]. - to sensitise communities about HIV testing and CPT's benefits (e.g. malaria prevention during pregnancy, prevention of opportunistic infections among babies born to HIV+ mothers) [34]. - to increase knowledge regarding the importance of IPT, its benefits and the purpose of taking it [64, 68]. - consider incorporating IPT into the training curriculum of undergraduate students [64]. • Encourage companies to support employee health to reduce stigma at the workplace [34]. • Strong commitment and strategic implementation support from policymakers and health authorities [67, 68]: <ul style="list-style-type: none"> - National advocacy for IPT [68]. - Stakeholder engagement: involving policymakers, higher level supervisors and health providers in the development of policies & guidelines, in the planning of resources for monitoring, the supervision and evaluation of outcomes particularly needed for the effective implementation of IPT [68]. - Planning for policy implementation: according to the target dimension (e.g. piloting, large scale roll-out) and ensuring additional resources depending on the complexity of the intervention (e.g. CPT<IPT) [56]. • Monitoring & Evaluation (M&E) of the implementation [56]: <ul style="list-style-type: none"> - Clearly defined, standardised indicators to evaluate the implementation progress (i.e. IPT programme) [67]. - Decentralised responsibility of M&E (e.g. long term external oversight from district level management) [51]. - Need for (informatic) tools and skills for routine tracking of data (e.g. initiation, coverage) [59]. - Sharing summary data with higher-level health authorities (district team, provincial team, MoH) [59]. - Need for a well-defined feedback mechanism of reporting indicators [68]. - Reflecting on results, adapting the implementation process if necessary [56]. • Ensuring national and regional policies exist on: <ul style="list-style-type: none"> - Stigma reduction strategies at the patient and community level (e.g. education about HIV, TB and the concept of prevention through teaching in schools, mass media, lectures on the radio, TV, skill building for potential perpetrators of stigma, involving peers) [34]. - Strict policies for providers on patient confidentiality and supportive service provision [63]. - HIV service integration (with TB care, family-, well-child- & maternal health care) [34, 37, 38, 40, 44, 46, 50]. - Assessment of patients migration, travelling and relocation intentions and directions on how providers should proceed (e.g. clinic transfer, therapy prescription of >2months in advance) [50, 61]. - Defining HIV service delivery strategy for vulnerable groups (i.e. commercial sex workers) [58]. - Financial relief for PLHIV (subsidised transport to the clinic, free consultation, free treatment) [62, 63]. - Social security benefits (e.g. disability grants for HIV/ AIDS, child support for caregivers of HIV+ children, nutritional support, food-partnerships with farmers, gardening or sustainable nutrition programmes) [63]. - IPT policy modification and adequate dissemination [54]. <p>Consider Policy update for IPT</p> <ul style="list-style-type: none"> • Considering (local, regional, national) lessons learnt for policy development of IPT delivery strategies [46, 63] <ul style="list-style-type: none"> - to identify specific target groups for scaling-up IPT (e.g. children and adolescents with HIV) [55, 59] • Involving health providers in the development of the IPT guidelines to promote their agreement with IPT [68] • Define set of minimum criteria to be met for IPT enrolment, such as: <ul style="list-style-type: none"> - Acceptance of HIV diagnosis [50] or openness about HIV status [63]. - Adherent to other intensive treatment regimen (e.g. ART) [50, 63]. - Regular clinic attendance (e.g. for at least 3 months or 4 visits) [63]. - Counselling for patients newly diagnosed, or not yet on ART, before IPT initiation [50]. - Requirement to attend support groups or linking HIV+ patients to community tracing [63]. • Allowing more time for patients to accept their HIV diagnosis before enrolment in intensive treatment regimen [61, 63]. • Simplifying and clarifying IPT policy [14, 51, 54, 67]: <ul style="list-style-type: none"> - Eligibility criteria; How to rule out active TB [54], role of chest radiography [54]. - Consider using the WHO symptom screening algorithm (TST, chest radiology not mandatory) [47, 67]. - Necessity to provide IPT together with pyridoxine [68]; monthly versus 3-monthly INH drug refills [68]. - Health provider considerations before initiating IPT (e.g. clinical state, concurrent drug regimen) [68].
----	--

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Strengthen clinical information systems

- Allocate resources to data collection, data recording and data management (e.g. data clerks, stationery items) [14, 45].
- Update and ensure the distribution of tools (paper-based or electronic) to record IPT and patient information [45].
 - Paper-based IPT monitoring tool (that allows recording patients' TB screening information prior to and upon IPT completion, side effects, documenting last drug pickup, refill periods [57].
 - Mobile application developed by WHO or adapting the app to local needs to improve recording of IPT [62].
 - Ensure tools allow efficient recording of patient information (e.g. integrated ART/ IPT registers and prescription forms) [14, 57], patient tracing between clinics and patient loss to follow-up [56].
 - Ideally one file held per patient in semi-integrated/ integrated facilities [37, 38].
- Improve reporting accuracy [67]:
 - Clearly written instructions to guide providers in recording of clinical data [42].
 - Conducting periodic surveys of patient cards to ensure the quality of routine recording [38].
- Consider the implementation of an electronic medical record (EMR) system if the following minimum system requirements are met: adequate data quality, reliable electricity, hardware & supplies, functional printers [45].
- Monitoring of risks (i.e. adverse reactions, drug interactions) and benefits of PT's [46, 50, 63].
- Monitoring of antimicrobial resistance [35, 52].

Pharmaceutical management

- Consider the authorisation of shorter TB preventive therapy regimen recommended by WHO [67, 68].
- Consider the use of ART/INH combination therapy in one tablet [64] or combined pre-packaging of ART and INH [43].
- Strengthen central procurement & supply chain management; Empower district TB office to procure INH locally [62].
- Consider authorising dispense of INH at referral centres closer to patients' homes [62].
- Considering potential peaks of INH demand (1. during scale-up, 2. when patients turn eligible for a repeat course) [57].

Service delivery considerations

- Patient-centred approach [66]:
 - Facilitate good and trusting health provider-patient relationship [50, 61, 63].
 - Ensuring patients' confidentiality (e.g. avoiding different queues or consultation rooms for HIV services at the health centre [64], or deliver HIV services separate from the general outpatient facility [34, 63].
- Empowering patients through knowledge and education [34, 48, 59, 63, 64]:
 - General information: living healthy with HIV, the concept of prevention and that PT is taken when asymptomatic [50]. TB risk and TB prevention [31, 36, 46].
 - Information about CPT [31]: Benefits - prescribed for preventing infections or 'to strengthen patients with low immunity', discouraging self-medication and pill sharing [35], importance of taking the correct drug amount, adherence to CPT during the prescribed duration [35], CPT can be used concurrently with ART and TB treatment [31], safety of CPT and potential side effects, side effects that require interruption of CPT, and that there is an alternative medicine (dapsone) [31].
 - Information about IPT [44, 46, 50, 58, 65]: Benefits, e.g. prescribed for preventing TB and not to alleviate symptoms [50, 67], importance of IPT [60], adherence to IPT, correct administration and duration of IPT [50], concurrent use with other treatments (e.g. ART), potential side effects (some treatable with pyridoxine), side effects requiring therapy interruption [50], encouraging reporting of side effects or complaints [50].
- Consider alternative approaches to deliver PT's:
 - TB/HIV service integration (requires close relationship between TB and HIV programmes, political will and considerable routine planning, coordination and monetary efforts [38, 44, 46, 55, 68].
 - 'Directly observed therapy' (DOT) approach for IPT [64].
 - Pharmacists delivering IPT (i.e. TB symptom screening, patient education, prescription and follow-up) [43].
- Develop patient education materials and ensure their distribution and availability at the health facilities [31].
- Consider establishing an initiative that engages patients' cultural, religious and spiritual beliefs (e.g. engage traditional healers to work alongside health providers in the clinic environment) [8].

Health system financing

- Financial commitment of Ministry of Health & donors [56] to fund HIV response [56], TB/HIV service collaboration [54].
- Additional funds needed for employment of health providers [14, 56], commodities and lab facilities [56].

Strengthen health provider capacity and knowledge

- Additional employment & shifting tasks to lower cadre to scale up HIV care and PT [15, 32, 38, 41-44].
 - Ensuring a reasonable patient-provider ratio [51], hiring personnel dedicated to IPT related activities [68].
 - Involving nurses [41], lay counsellors [42], pharmacists [43], social- and community workers [44], as well as PLHIV [32, 38] (i.e. peers, expert patients) to provide psychological support, PT, basic tasks, dispense tablets.
- Ensuring provider training & refresher training [14, 15, 36, 38, 42, 44, 46, 51, 53, 54, 66].
- Improving the working conditions of health providers (e.g. work environment, reduce provider workload) [67, 68].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F2	<p>Entry to health facility: Strategies to enhance patients' willingness and feasibility to enter public healthcare</p> <ul style="list-style-type: none"> • Welcoming and safe clinic environment, friendly and supportive health providers [63, 66]. • Making visits brief & convenient (i.e. offering all services on all clinic days, adding weekend clinic hours) [46, 48]. • Ensuring patients' confidentiality to reduce the fear of stigma/ discrimination [34, 42, 63]. • Encouragement & advice from peers (post-test club, support groups) [44, 63]. • No clinic consultation fees; no dispensing fees for patients with chronic diseases (i.e. HIV) [38, 63]. • Building incentives into service delivery (e.g. subsidized transport/ reimbursement, nutritional support) [60, 61, 63, 65]. • Family & community support and encouragement (emotional, financial, organisational support) [34, 50, 63]. • Consider integrating alternative medicine, church services, and family counselling into public health care if western medicine is not widely accepted (i.e. opposed by family, friends, church leaders, traditional medicine) [63]. • Providing patient information during pre-and post-test counselling [34, 44, 50, 60] or every clinic visit [36].
F3	<p>Eligibility: Strategies to increase health providers willingness and capability to determine patients' eligibility for PT's</p> <ul style="list-style-type: none"> • Empowering providers through training [14, 36, 38, 42, 44, 46, 51, 53, 54, 57, 62, 63, 66-68]: <ul style="list-style-type: none"> General information: <ul style="list-style-type: none"> - current epidemiology of HIV & TB [46, 53] and TB/HIV collaborative service provision [38]. - clinical particularities of TB/HIV co-infection [46], managing complex cases [39]. - current policies and guidelines regarding the treatment of latent TB, TB and HIV [51]. - public health importance of detecting and treating active TB among patients with HIV [46]. - How to facilitate nutritional support and social security grants [63]. - Communication skills (facilitating a good and trusting provider-patient relationship) [66]. Information on CPT: <ul style="list-style-type: none"> - CPT for HIV+ pregnant women [15, 36] and HIV-exposed babies [15]. Information on IPT: <ul style="list-style-type: none"> - Benefits of IPT [67], importance of IPT/ treating latent TB among patients with HIV [46, 51]. - Present current research consensus supporting IPT [46], showing IPT does not promote INH resistance [54]. - How to rule out TB and determine if patients are eligible for IPT. - Increase providers' confidence [53], capability [67] and motivation to prescribe IPT [67]. - Managing side effects and supporting patients to complete IPT [66]. - Difference between tuberculin and BCG vaccine (if applicable) and monitoring the tuberculin cold chain [49] • Measures to improve health providers' acceptability of IPT [68], their confidence and motivation to prescribe IPT: <ul style="list-style-type: none"> - Mentorship [51, 53, 57, 64], supportive supervision [46, 53, 57, 68] (e.g. from district level coordinators [51]), selecting and training an 'IPT champion' [51, 54], text messaging reminders of key criteria to determine IPT eligibility [51], ensuring a consistent supply of INH and pyridoxine [53]. - Involving local opinion leaders to change providers perception about IPT [48]. • Ensuring capacity for TB diagnosis & TB treatment essential for provision of IPT (i.e. adequate number of trained providers, facility infrastructure, ensuring a consistent supply of drugs) [14, 45, 53]. • Ensuring guidelines are well written, understandable and available at the health facility level [36, 53, 68]. • Ensuring routine evaluation and re-evaluation of patients' eligibility for IPT [43, 64]. • Availability of IPT recording tool (e.g. IPT register/ monitoring tool) [57]. • Tools to document IPT status (e.g. sticker reminder on patient file) [57]. • Tools to guide IPT decision making (e.g. paper-based work aid, or embedded electronic tool) [45].
F4	<p>Provision: Strategies to enhance health providers' prescribing practices of PT's (particularly IPT)</p> <ul style="list-style-type: none"> • Closing providers' knowledge gaps and enhancing their attitudes towards PT (particularly regarding IPT): <ul style="list-style-type: none"> - Educational campaigns & advocacy activities that include evidence basis and involve local opinion leaders, 'IPT champions' setting an example, prescribing IPT; positively influencing attitudes toward IPT [45, 46, 54, 66]. • Visible leadership, supervision and support of health providers: <ul style="list-style-type: none"> - Roles & responsibilities in PT provision clear [42, 63]. - Reinforcing national guidelines, provider encouragement by IPT champion and at weekly group meetings [51]. - One-on-one mentorship & supervision with feedback to support continuous skill acquisition and health providers' confidence to deliver tasks (e.g. ruling out TB, recording patient information, prescription of PT, prepare for- and managing side effects, treatment decisions for complex cases) [39, 46, 49-51, 53, 54, 67]. - Quality improvement approach to identify problems and take corrective action (teaching basic concept, routine data collection, chart analysis, weekly collaborative meetings to discuss successes and challenges) [57, 66]. - Quarterly site visits for record review (e.g. organised by district TB, HIV programme managers) [57, 64]. • Empowering patients to ask for IPT (e.g. posters and health education sessions at the health facility) [51]. • Review the process of PT delivery [49], tailoring it to the clinic routine [67], considering contextual challenges [68]: <ul style="list-style-type: none"> - Participatory approach (involving health providers) [49, 67], generation and use of data, lessons learnt [57]. - Consider reorganising services, improving patient flow within the clinic to avoid long waits [46, 56, 63].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

F5	<p>Availability: Strategies to improve the availability of PT's at public health facilities and pharmacies</p> <ul style="list-style-type: none"> Focus on ensuring the availability of CTZ and INH [14, 45, 50, 51, 64]: <ul style="list-style-type: none"> Improving technical and logistic capacity at health facilities [68]. Personnel responsible for inventory management, stock audits & the availability of stock at each level [45, 50]. District level initiatives to improve INH availability (e.g. monthly monitoring of INH) [51]. Improving supply chain management [14, 15, 45, 53, 57, 68]. Implementing a stock inventory management system [36], detailed accounting of stock supplies at all levels [45]. Quantification and demand forecasting [36]; include back-up stock (additional buffer) [45]. Routine stock audits to identify & address INH stock-outs at health facilities and pharmacies [65]. Developing stock capacities centrally, decentralised and at the health facility level [33, 45]. Health facility approach for insufficient stock: <ul style="list-style-type: none"> Prioritising patient subgroups (e.g. based on CD4 count, compliant with clinic visits, adherence to ART) [62]. Earmarking drugs for a full course of IPT (e.g. 6-months) for each patient who initiated IPT [57, 62]. Health facility approaches in case of stock-outs: <ul style="list-style-type: none"> Informing patients about stock-outs to avoid confusion (e.g. patient may think he/she completed PT) [50]. Prescribing alternative formulation of CTZ/ INH (e.g. tablets instead of suspension for children) [15]. Advising patients to return when stock is available [15] or buy CTZ/ INH in private pharmacies [15, 35, 36, 38].
F6	<p>Adherence: Strategies to enhance patients willingness and feasibility to adhere to PT's</p> <ul style="list-style-type: none"> Individual assessment of patients' needs, concerns and feasibility to initiate IPT: <ul style="list-style-type: none"> Consider initiating IPT at the time of HIV diagnosis [55]. Need for providers to discuss patients' feasibility of (e.g. monthly) clinic visits, and offer PT based on individual assessment of patient's needs, concerns and commitment to follow clinic visits [15, 50, 61]. Discussing patients' travel plans (e.g. consider prescribing >2months of IPT for patients who will travel [50]. Facilitate clinic transfer between different cities/ provinces or allow treatment supply in advance [50]. Allowing more time before enrolling patients into intensive treatment regimen (if policy & guideline allows) [44, 63]. Educating patients before initiating IPT [64]: <ul style="list-style-type: none"> Risk of developing TB, importance of IPT, side effects; dapsons, pyridoxine to manage side effects [31, 50, 64]. Encouraging patients to report problems or complaints [50], support patients in managing side effects [64]. Encourage patients to disclose HIV diagnosis to a trusted person or family member [63]. Health facility support services: <ul style="list-style-type: none"> Support groups, nutritionist, food parcels, multivitamins [63], transport support [62, 63]. Couple testing [34], Involvement of partner/ friend during initiation of IPT; ensuring family approval of PT [34, 60]. Patients' adherence support: <ul style="list-style-type: none"> Social support or feeling comfortable taking PT in front of others [34, 36, 40, 60, 66]. Reminder systems developed by patients (e.g. phone alarms [34, 61], marking a calendar [61]). Adherence club member collects ART and INH for the group members [64]. Health facility-based adherence support: <ul style="list-style-type: none"> clinic visit reminders or follow-up by health providers (e.g. through phone calls, home visits to follow up and encourage defaulters/ community tracing) [36, 44, 53, 61, 63]. Adherence assessment (patient self-report, pill counts during treatment refills, INH metabolite testing) [36, 65]. Provider encouragement and follow-up to adhere to PT [53, 64].
F7	<p>Retention in care: Strategies that encourage patients' completion of PT</p> <ul style="list-style-type: none"> Patients self-motivation: <ul style="list-style-type: none"> Belief that PT is useful improves health status or is important to prevent disease [31, 34, 50, 60, 64, 66]. Belief in personal health threat or fear of disease (e.g. concern about family) [34, 61]. Belief in the effectiveness of health care, understanding the importance of PT's. Acceptance of HIV status, disclosure to supportive person, comfortable to take PT in front of others [58, 61, 63, 64]. Reducing patients' need to travel to multiple clinics: <ul style="list-style-type: none"> Same-day appointments for family members [34]. HIV service integration with other services (e.g. providing ART + IPT; TB treatment + CPT at the same time and location) [38, 43, 46, 50, 68]. Reducing patients' frequency of health facility visits and medication pickups: <ul style="list-style-type: none"> Differentiated care: e.g. quarterly clinic attendance for clinically 'stable' PLHIV [50, 66]. Home visits or home-based care (with health facility referral of complex cases) [36, 66]. Adherence club member collects ART and INH for the group of members [64]. Positive attitudes of health providers or good provider-patient relationship [64]. Patient follow-up or linking HIV+ patients to community tracing in case they miss clinic appointments [53, 63].

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

Discussion

In high TB/HIV burden countries, both preventive therapies in the centre of this review (i.e. CPT, IPT) are key interventions for PLHIV that can save lives if administered together with ART, or even on their own [6, 9]. However, governments of high TB/HIV burden countries face major implementation challenges that limit the effectiveness of both preventive therapies [16-18]. We explored and compared both preventive therapies with respect to similarities and differences of barriers identified across high TB/HIV burden countries published in peer-reviewed literature. Additionally, we explored and summarised strategies (facilitators) with the potential to tackle the identified barriers.

Similarities and differences in barriers

Detailed barrier description presented in this review offered various explanations to why the implementation of both preventive therapies has been so challenging in the concerned countries. However, careful analysis of the extracted barrier information showed that many barriers were very similar for both preventive therapies. Our metasummary findings showed that the majority of barrier themes (25/32) that emerged from this review were identical for CPT and IPT and thus not intervention-specific (Figs 3 and 4). This leads to the question: "What are the underlying patterns of these cross-cutting barrier themes?" Taking into consideration that cross-cutting barrier themes were scattered across all building blocks of the health system and rather generic in nature indicates that systematic weaknesses within the health system may be an important underlying reason for implementation struggles. All barrier reporting studies (N=37), except one [52], reported such cross-cutting barriers, which at least hints that many high TB/HIV burden countries' health systems were weak and unable to meet the basic requirements of a well-functioning health system [27]. Fragile public health systems could be explained by the fact that more than three-quarters of the countries with a high burden of TB and HIV are low- and lower-middle-income countries (as per 2021 World Bank's classification) [69]. Many of these

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

countries have severely constrained health budgets and historically depend on foreign assistance [70]. Following two decades of increasing domestic and generous international funding that has been mainly channelled into vertical health programs, impressive gains have been achieved in reducing AIDS-related deaths [27]. However, health systems strengthening is not characteristic for vertical funding and healthcare organisation. A major concern is that impressive gains of the past have been neither universal, nor sustainable [27]. We speculate that the sustainability of the HIV response and health facility-based delivery of both preventive therapies will become more challenging over the next years. The dilemma is that funding from international donors is flatlining [70], while an increasing number of HIV patients require life-long medical care [71] to be delivered by vertical programs that have long reached the limit of their effectiveness. Others have claimed that strengthening weak public health systems in the developing world is the next 'emergency' and an inevitable step to sustain the progress achieved in the last two decades [72]. At this stage of understanding, we believe it is quite possible that health system constraints identified for CPT and IPT, similarly hinder the implementation of other health facility-based interventions in high TB/HIV burden countries. Therefore, in addition to intervention-specific barriers, context-specific health system constraints should be considered to move towards a more feasible implementation strategy.

Like for CPT, barriers identified for IPT were most frequently classified as 'service delivery-' or 'patient & community related'. Typically, 'service delivery related barriers' were interrelated with constraints identified across other health system components. For instance, with inaccurate clinical information, insufficient health providers and frequent drug stock-outs, efficient and reliable delivery of preventive therapy is unrealistic. These interrelations highlight that service delivery strongly depends on a well-functioning interplay of the health system components represented in the original WHO's Framework for action [27]. We observed that barriers identified across the six original health system components (i.e. health workforce, information systems, essential medicines, financing, leadership/ governance,

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

service delivery) represented constraints on the supply side. Meanwhile, 'patient and community-related barriers' comprised limitations that limited the demand of preventive therapies, hindering patients from entering healthcare, leading to inconsistent clinic visits or therapy interruptions. Among all 'patient and community-related barriers', we would like to draw special attention to 'lacking financial and organisational feasibility'. This barrier theme was supported by more than one third of all studies included in this review [12, 15, 16, 22, 23, 25, 28, 31, 40-45], suggesting that in resource-constrained countries and in the context of poverty, free provision of health facility-based services may not be sufficient to ensure equitable access to healthcare. The economic impact of COVID-19 is expected to further decrease patients' average household income in the coming years, posing an increasing threat to their ability to commit to frequent health facility visits and medication pickups. Summarising the above, barriers to both, CPT and IPT were most frequently classified as 'service delivery-' or 'patient & community related', representing supply- and demand-side constraints that introduce complex, interrelated dynamics [73]. Therefore, we emphasise the value of a 'seven component health system framework' for the purpose of barrier exploration and the formulation of an implementation strategy that is tailored to address potential barriers on the supply- and demand-side.

We also revealed some differences between barriers to both preventive therapies. Overall, our review suggests that implementing IPT has been more troublesome than CPT, supported by overall more barrier themes and evidence reporting barriers to IPT. This is consistent with the cross-sectional study carried out by WHO HIV/AIDS programme officers in 2007 [74], which showed that less progress had been made in implementing IPT when compared to CPT at the time. Thus, more research focus may have been on IPT since. Nevertheless, we argue that there is also more complexity involved in the eligibility assessment and provision of IPT compared to the more straightforward provision of CPT. Implementing IPT requires a higher degree of coordination; its delivery involves multiple steps, requires particular skills and seems to depend on additional capacity (particularly

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1381 human resources) to follow-up patients who initiated IPT and those with a positive TB
1382 screening result.

1383 Considering challenges specific to implementing IPT, 'health provider related barriers'
1384 appeared to play an important role. Our review revealed that having to rule out active TB
1385 disease was an important issue for the implementation of IPT. First, local policies and
1386 guidelines were described as unclear, so that health providers lacked knowledge and
1387 confidence in determining who is eligible for IPT [14, 68]. Second, health providers appeared
1388 to be overwhelmed with this additional task of routinely assessing and documenting patients'
1389 eligibility [38, 51]. Third, while health providers attitudes towards CPT seemed neutral or
1390 positive, providers' attitudes and beliefs toward IPT were partially negative [14, 44, 45, 53,
1391 54, 62, 64, 67, 68]. One health provider concern was that extrapulmonary TB, common
1392 among PLHIV, may go undetected when screening for pulmonary symptoms [54]. Some
1393 health providers appeared to be unconvinced whether the benefits of IPT outweigh the risks
1394 of side effects [14, 53, 68] or of promoting INH resistance [45, 54, 64, 68]. Studies carried
1395 out in sub-Saharan Africa reported that some health providers had refused to prescribe IPT
1396 because of their fear of promoting INH resistance [54]. Overall, the use of preventive
1397 therapies has often been controversial, with concerns about drug resistance forming one
1398 major barrier to policy development and implementation [75]. However, it was somewhat
1399 surprising that studies reported health providers' concern about bacterial resistance for IPT
1400 [45, 54, 68], but not for CPT. Notably, many high TB/HIV burden countries witness a high
1401 burden of MDR-TB [2]. Instead of INH monoresistance, health providers' genuine concern
1402 may thus lay in promoting MDR-TB among patients with HIV [54]. Another surprising barrier
1403 theme identified specifically for IPT was provider-patient communication [50, 51, 58], which
1404 could indicate that communication needs are greater for IPT. However, only three studies
1405 reported issues with provider-patient communication regarding IPT [50, 51, 58]. Therefore,
1406 this barrier could also be indicative for changing patient expectations. A popular explanation
1407 is that the patient-provider relationship has changed over time. Health providers are no

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

longer seen as the dominant decision-makers and patients as passive service recipients (i.e. paternalistic model) [76]. Instead, patients expect and are expected to be actively involved in their therapy decision [76]. Based on our review findings, patients were often afraid to speak to health providers about IPT [50, 51, 58], suggesting that providers may require additional training in how to develop a trusting provider-patient relationship and encourage their patients to address any arising concern. With the increasing global interest in TB prevention [2], several studies have been dedicated to assessing socio-demographic, lifestyle- and clinical factors associated with HIV patients' chances of initiating, receiving, completing or adhering to IPT [14, 46, 48, 55, 58-60, 62, 66, 68]. These studies highlight key populations that may benefit from tailored implementation approaches. Another important factor for the implementation of IPT is that, in contrast to CPT, IPT requires greater coordination between HIV and TB program at all levels. Many high TB/HIV burden countries have implemented symptom-based screening to determine patients eligible for IPT [47], which is believed to have significantly advanced IPT uptake in low-resource settings [53]. On the one hand, symptom-based screening enabled HIV services units to take greater responsibility for implementing IPT. However, findings of the studies included in this review suggest that TB services' capacity and linkage was too weak to follow-up patients with presumptive TB and to ensure immediate TB treatment for patients with confirmed TB [14, 38, 45, 49, 52, 54, 64, 67]. This leads to another challenge that is particular for IPT; it requires collaboration and capacity for the co-management of TB.

Considering challenges specific to the implementation of CPT, we found that bacterial resistance was a concern raised by the authors of a study included in our review [35]. Mwambete and Kamuhabwa (2016) questioned the efficacy of CTZ in areas of high bacterial resistance as a result of their research findings. Based on the disk diffusion method, their study identified an overall high resistance of isolated enteric *E. coli* among HIV patients in Tanzania [35]. Although antimicrobial resistance is a topic of utmost urgency, there are reasons to doubt the urgent need to reconsider the use of CPT in high TB/HIV

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

burden countries. On the one hand, the in-vitro assay applied in the study [35] is no longer the gold standard for antimicrobial susceptibility testing because it often disqualifies antibiotics that are, in fact, effective in-vivo [77, 78]. On the other hand, several studies have shown significant reductions in morbidity and mortality among PLHIV on CPT, despite the fact that they were carried out in settings with high bacterial resistance. Therefore, others have argued that in-vitro resistance testing undermines the prophylactic ability of CTZ [79]. Finally, one study included in our review suggested a lack of written instructions for patients, referring to missing documented strategies for ensuring the availability of CTZ at the health facilities and patient leaflets that list potential adverse reactions that require therapy interruption [36]. Although we revealed several knowledge gaps and misperceptions among patients in our review that could be addressed in written instructions, the provision of patient information leaflets, in general, is not yet standard practice in many low- and middle- income countries [80]. One popular explanation for the under-utilisation of information leaflets at public pharmacies is that they are poorly understood [81]. Poor understanding may be more pronounced among populations with low literacy, which may have led to low prioritisation of creating such written information in the concerned countries. However, in combination with pictograms, basic written information has shown valuable for educating patients about CPT [80]. Nevertheless, such patient leaflets are still not available in all countries, reemphasising the importance of effective provider-patient communication during direct patient contact.

Facilitators to preventive therapies

As barriers vary between and within high TB/HIV burden countries, there is not one strategy for improving the implementation of either or both preventive therapies that fits all settings. We, therefore, encourage redesigning an implementation strategy that addresses barriers identified in a specific context. The awareness of implementation challenges and political williness to tackle these issues are critical first steps for continuous improvement. Routinely collected indicators, district-level evaluations, dialogues with implementers or local

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

research findings may indicate difficulties with the implementation of one or both preventive therapies on a national level or in a specific setting. Our review identified only a few intervention-specific barriers and highlighted that cross-cutting barriers often affect the implementation of both preventive therapies and potentially other interventions in high TB/HIV burden countries. On the one hand, the resulting awareness that strategies are needed to target systematic weaknesses, as well as an intervention on its own, can be daunting. On the other hand, integrating the concept of health systems strengthening into an implementation strategy provides new opportunities for policymakers and health systems. These opportunities include improvements in health system sustainability, effectiveness and the availability of international support for health systems strengthening.

First, health systems strengthening may still appear unrealistic in low-income countries where primary care facilities struggle to provide basic health services and essential medicines. Additionally, funding mechanisms have partially encouraged vertical health system organisation and made it more difficult for health systems strengthening to be achieved in low- and middle-income countries. However, the decision for ‘organisational transformation’ is not based on the capacity of an individual primary care facility but rather, the potential behind removing cross-programmatic duplications and leveraging the existing resources. Transforming a health system structurally from fully vertical (e.g. disease-specific) programmes into a horizontally organised health system should be a gradual process. Similarly, others have argued that a phased, targeted and incremental transition from a vertical HIV response to a more efficient and sustainable health system response should be the way forward [71]. Adapting the implementation strategy of a high-impact multi-programmatic intervention, such as IPT, provides an opportunity to contribute to a more sustainable health system transformation.

Second, we understand that health systems strengthening is ambitious to achieve holistically, is difficult to measure and can be expected to take a long time. However, targeted strengthening of a selected health system component, such as up-skilling

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

leadership and governance, reinforcing health providers' capacity and knowledge, strengthening supply chains or health information systems comprise examples frequently identified in this review with the potential to yield benefits across both preventive therapies and a wide range of other health interventions. In addition, strengthening an individual health system component can help relax capacity constraints, result in cost-sharing, increase efficiency and cost-effectiveness of individual interventions. Cost-effectiveness analysis can assist in establishing the optimal balance between systems strengthening- and intervention-specific approaches to be included in an implementation strategy [82].

Third, vertical programmes of the past were popular for their 'quantifying of lives saved' approach that promised and short term objectives that promised quick and measurable results [83]. However, disease-specific programmes and initiatives were criticised for their costly parallel structures, less sustained impact, and for negatively affecting non-HIV care [72, 83]. In high TB/HIV burden countries that depend on external funds to finance their HIV response, vertical programming was associated with donor-driven policy evolution and investment decisions that were not always aligned with national priorities [56]. 'Pushing' global recommendations without considering context-specific constraints undermines the competence of local policymakers and can create tension between donors and recipient countries' governments and weaken local policy ownership. For example, instead of prioritising prevention activities, donors' investment focus was considered primarily strong on medicines, without adequate consideration of health system capacity (e.g. human resources) on which the delivery of these medicines is dependent [14, 56, 71].

However, many of these issues have been recognised internationally, and the global health systems strengthening movement has finally gained momentum [84, 85]. Major HIV funding bodies (i.e. USAID, Global Fund) have begun promoting the 'de-verticalisation' of fragmented programming [84, 86]. Both, the U.S. Agency for International Development (USAID) and the Global Fund to fight AIDS, TB and Malaria (Global Fund) have incorporated

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

systems strengthening objectives into their strategy [84, 86] and updated their policies to include funding agreements for health systems strengthening that allow direct disbursement of funds to the recipient country's state budget [83, 87]. Dialogues between donors and local system stakeholders (e.g. USAID's Government to Government (G2G) assistance, Global Fund's country coordinating mechanism (CCM)) support alignment of policies with country priorities [83, 87], encouraging mutually beneficial decisions and better relationships between donors and recipient countries. Additionally, the new implementation science culture encourages consideration of national, regional and local lessons learnt [46, 63, 88]. To sum up, the foundation for change has been laid. It is now up to high burden countries' governments to make best use of the support and domestic resources available for health to collaboratively select, plan and coordinate an implementation strategy that addresses context-specific barriers and maximises the likelihood of long-term sustainability of both interventions.

Strengths and limitations

The main strength of this review is the in-depth understanding that this review provides about the challenges associated with the implementation of CPT and IPT in countries with a high burden of TB and HIV. To explore the existing body of evidence holistically, (1) we applied a comprehensive search strategy, (2) included all stakeholders involved in the implementation process as study population, (3) integrated research with different study designs, and (4) presented the identified barriers within each of the building blocks of the health system. First, we systematically searched three databases, using a combination of MeSH and free-text terms. In addition, we manually screened reference lists of systematic reviews for original research eligible for this review. Second, our review included studies that reported the perspectives and experiences of any stakeholder involved in the implementation process, encompassing patients' and health providers' views that are otherwise often disregarded in the implementation process. Third, the integration of studies

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

with different study designs further enhanced the richness of our findings. Mixed methods systematic reviews have gained increasing scientific attention in the areas of public health and complex interventions, where typically decision makers require consideration of different types of data and information (e.g. accessibility, feasibility, patient values and preferences) [18]. Fourth, for the qualitative evidence synthesis of barrier information, we applied a highly transparent deductive approach using an a priori defined coding framework of seven health system components (a modification of the WHO's Framework for action) [27]. Qualitative evidence synthesis is relatively new compared to quantitatively oriented systematic reviews and the application of metasummary to compare interventions with respect to similarities and differences of barriers employed in our review is innovative.

Potential limitations of our review include (1) restrictions in our search strategy, (2) methodological limitations of the included studies, (3) heterogeneity of study characteristics, and (4) potential biases introduced through the non-availability of studies or the non-dissemination of study findings. First, although our search strategy was systematic and rigorous, it only included peer-reviewed publications reported in the English language. This is unlikely to be a major limitation considering that twenty-three high burden countries were represented in this review. However, this may explain why most studies included in this review, were carried out in South Africa, Uganda and Tanzania. Only including peer-reviewed published studies may have led to the exclusion of potentially useful grey reports (e.g. HIV progress reports). Second, we did not exclude any study from our analysis regardless of the methodological limitations. However, we systematically assessed each study's strengths and limitations and carefully considered issues of bias, validity, and trustworthiness. Third, we identified a heterogeneous representation of the study populations represented in our review. Most of the included studies presented the perspectives of patients and health providers. Consequently, the views of caregivers, community members and other stakeholders involved in the implementation process were less frequently represented, limiting the generalisability of our findings. However, generalising findings was

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

outside the scope of this review. Therefore, the primary concern about this observation is the extent to which our findings holistically represent the phenomena of interest. Fourth, non-availability or non-dissemination of studies may have limited the completeness of our study findings [30]. Studies on the subject of this review may be less likely to be available in countries with limited political interest to implement the concerned preventive therapies. In high TB/HIV burden countries with little research capacity, available study findings may be more likely to be published in local journals that are not indexed in major databases.

Conclusion

There is little benefit to any highly efficacious therapy as long as we are unable to effectively implement it under ‘real-world’ conditions.

For policymakers who encounter challenges with the implementation of either or both preventive therapies, this review offers a list of strategies for improving the implementation of both preventive therapies. Based on evidence from high TB/HIV burden countries, this list includes specific direction for improving the delivery of IPT (or any newer therapy regimen) for the prevention of TB. For researchers with limited working experience in high TB/HIV burden countries, this review can provide useful insights regarding to which barriers may arise at different levels of the health system. The barrier description provided in this review highlights the complexity of social interactions involved in the delivery of preventive therapies.

Overall, our review showed that until today, many high TB/HIV burden countries’ health systems are not prepared to ensure appropriate public healthcare for the ever increasing number of patients in need of HIV services. From this standpoint, health system strengthening is imperative for the sustainable delivery of both preventive therapies for PLHIV, but particularly for IPT. Based on our findings, we suggest consideration of two important aspects to implementation. First, we recommend early engagement of

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

stakeholders when shaping an implementation strategy. Involving patients and health providers in the process of policy development and planning may increase awareness and understanding about the intervention and help to ensure its acceptability. Additional stakeholders (e.g. church leaders, traditional healers) may be involved, if appropriate. Second, during the adaptation of an implementation strategy, we urge that attention is paid to the fact that many of the countries with the highest burden of TB and HIV to date are also among the most resource-constrained countries. Thus, novel strategies for the implementation of preventive therapies may appear encouraging at first, but in high TB/HIV burden settings, they are often far from feasible or sustainable on a big scale. Instead, we encourage innovative approaches that consider the resources available at the health facility level, and investing into strengthening the existing capacities.

Future research is warranted to test and evaluate alternative service delivery approaches that reduce the financial and organisational burden that patients face during the course of preventive therapy. Replacing INH with one of the shorter treatment regimen recommended by WHO for the prevention of TB [13] and the community-based delivery of selected activities related to the provision of PT's may comprise two options with the additional benefit of reducing the patient load at the overburdened health facilities.

Funding

This study was funded by the Portuguese Foundation for Science and Technology (Fundação para a Ciência e a Tecnologia - FCT, www.FCT.pt), through funds to the Global Health and Tropical Medicine Research Center (Grant number: GHTM - UID/Multi/04413/2013). The study was supported by funds from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung – BMBF, <https://www.bmbf.de/>), through funds to the Hans-Böckler Stiftung (HBS). LVL was funded

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

1618 by the FCT grant. PM received a Research Scholarship from the HBS (PhD Scholarship ID:
1619 385759). The funders had no role in study design, data collection and analysis, decision to
1620 publish, or preparation of the manuscript.

1621 **Acknowledgement**

1622 We would like to express our gratitude to Jonathan O' Mahony for proofreading the
1623 manuscript. In addition, we would like to thank Carlos Rodrigues, IT specialist at the Institute
1624 of Hygiene & Tropical Medicine in Lisbon for his support with formatting the graphics
1625 included in this manuscript.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

References

1. UNAIDS. Global HIV & AIDS statistics - 2020 fact sheet. 2020. Available from: <https://www.unaids.org/en/resources/fact-sheet>.
2. World Health Organization. Global Tuberculosis Report 2020. 2020. Available from: <https://www.who.int/publications/i/item/9789240013131>.
3. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. The European respiratory journal. 2019;54(3). Epub 2019/06/22. doi: 10.1183/13993003.00655-2019. PubMed PMID: 31221810.
4. World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1. Prevention: Tuberculosis preventive treatment 2020. Available from: <https://www.who.int/publications/i/item/who-consolidated-guidelines-on-tuberculosis-module-1-prevention-tuberculosis-preventive-treatment>.
5. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. chapter 5: Clinical guidelines: Managing common coinfections and comorbidities.: World Health Organization; 2016. Available from: <https://www.who.int/hiv/pub/arv/arv-2016/en/>.
6. Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, et al. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. The Lancet HIV. 2015;2(4):e137-e50.
7. Geremew D, Endalamaw A, Negash M, Eshetie S, Tessema B. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC infectious diseases. 2019;19(1):405. doi: 10.1186/s12879-019-4031-2.
8. Eholié SP, Ello FN, Coffie PA, Héma A, Minta DK, Sawadogo A. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study. Tropical Medicine and International Health. 2017;22(9):1186-95. Epub 2017/06/28. doi: 10.1111/tmi.12919. PubMed PMID: 28653454.
9. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. The Lancet Global Health. 2017;5(11):e1080-e9.
10. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane database of systematic reviews. 2010;(1). doi: 10.1002/14651858.CD000171.pub3.
11. World Health Organization. Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. African Health Sciences. 2000;1(1):30-1.
12. WHO/ UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV 1998. Available from: https://apps.who.int/iris/bitstream/handle/10665/64509/WHO_TB_98.255.pdf?sequence=1.
13. World Health Organization. Tuberculosis. Key facts 2020. 14 October 2020:[Available from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1672 14. Mugomeri E, Olivier D, Van Den Heever WM. Health system challenges affecting the
1673 implementation of isoniazid preventive therapy in people living with HIV in Lesotho.
1674 HIV and AIDS Review. 2018;17(4):299-307. doi: 10.5114/hivar.2018.80263.
- 1675 15. Kamuhabwa AAR, Manyanga V. Challenges facing effective implementation of
1676 cotrimoxazole prophylaxis in children born to HIV-infected mothers in the public
1677 health facilities. Drug, healthcare and patient safety. 2015;7:147-56. doi:
1678 10.2147/dhps.s89115. PubMed PMID: WOS:000215804900017.
- 1679 16. Thabane L, Thomas T, Ye C, Paul J. Posing the research question: not so simple.
1680 Canadian journal of anaesthesia. 2009;56(1):71.
- 1681 17. Butler A, Hall H, Copnell B. A guide to writing a qualitative systematic review protocol
1682 to enhance evidence-based practice in nursing and health care. Worldviews on
1683 Evidence-Based Nursing. 2016;13(3):241-9.
- 1684 18. Joanna Briggs Institute. JBI Reviewer's Manual. Chapter 8: Mixed methods
1685 systematic reviews. Section 8.5.1 Mixed methods systematic review using a
1686 convergent integrated approach to synthesis and integration. 2017 [cited 1]. Available
1687 from:
1688 [https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+](https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration)
1689 [using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration](https://wiki.jbi.global/display/MANUAL/8.5.1+++Mixed+methods+systematic+review+using+a+CONVERGENT+INTEGRATED+approach+to+synthesis+and+integration).
- 1690 19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
1691 reviews and meta-analyses: the PRISMA statement. Annals of internal medicine.
1692 2009;151(4):264-9.
- 1693 20. Cumpston M, Chandler J. Chapter IV: updating a review 2019. Available from:
1694 <https://training.cochrane.org/handbook/current/chapter-iv>.
- 1695 21. Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed
1696 methods appraisal tool (MMAT), version 2018. User guide. 2018. Available from:
1697 [http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)
1698 [2018_criteria-manual_2018-08-01_ENG.pdf](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf).
- 1699 22. Noyes J, Booth A, Flemming K, Garside R, Harden A, Lewin S, et al. Cochrane
1700 Qualitative and Implementation Methods Group guidance series - paper 3: methods
1701 for assessing methodological limitations, data extraction and synthesis, and
1702 confidence in synthesized qualitative findings. Journal of clinical epidemiology.
1703 2018;97:49-58.
- 1704 23. Hannes K. Chapter 4: Critical appraisal of qualitative research: Cochrane
1705 Collaboration Qualitative Methods Group, 2011; 2011. Available from:
1706 <http://cqrmg.cochrane.org/supplemental-handbook-guidance>.
- 1707 24. Sandelowski M, Barroso J, Voils CI. Using qualitative metasummary to synthesize
1708 qualitative and quantitative descriptive findings. Research in nursing & health.
1709 2007;30(1):99-111.
- 1710 25. Petticrew M, Rehfuess E, Noyes J, Higgins JP, Mayhew A, Pantoja T, et al.
1711 Synthesizing evidence on complex interventions: how meta-analytical, qualitative,
1712 and mixed-method approaches can contribute. 2013;66(11):1230-43.
- 1713 26. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, et al.
1714 Implementation of isoniazid preventive therapy for people living with HIV worldwide:
1715 barriers and solutions. AIDS. 2010;24:S57-S65.
- 1716 27. World Health Organization. Monitoring the building blocks of health systems: a
1717 handbook of indicators and their measurement strategies: World Health
1718 Organization; 2010. Available from:
1719 https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1720 28. Asonganyi E, Vaghasia M, Rodrigues C, Phadtare A, Ford A, Pietrobon R, et al.
1721 Factors affecting compliance with clinical practice guidelines for pap smear screening
1722 among healthcare providers in africa: systematic review and meta-summary of 2045
1723 individuals. PLoS ONE. 2013;8(9):e72712. Epub 2013/09/27. doi:
1724 10.1371/journal.pone.0072712. PubMed PMID: 24069156; PubMed Central PMCID:
1725 PMCPMC3771969.
- 1726 29. Petticrew M, Egan M, Thomson H, Hamilton V, Kunkler R, Roberts H. Publication
1727 bias in qualitative research: what becomes of qualitative research presented at
1728 conferences? Journal of Epidemiology and Community Health. 2008;62(6):552-4.
1729 doi: 10.1136/jech.2006.059394.
- 1730 30. Booth A, Lewin S, Glenton C, Munthe-Kaas H, Toews I, Noyes J, et al. Applying
1731 GRADE-CERQual to qualitative evidence synthesis findings—paper 7: understanding
1732 the potential impacts of dissemination bias. Implementation Science. 2018;13(1):12.
1733 doi: 10.1186/s13012-017-0694-5.
- 1734 31. Okwera A, Mafigiri DK, Guwatudde D, Whalen C, Joloba M. Level of understanding
1735 of co-trimoxazole use among HIV infected, recurrent pulmonary tuberculosis
1736 suspects at a national referral tuberculosis clinic in Kampala, Uganda: a qualitative
1737 analysis. Afr Health Sci. 2015;15(1):49-57. Epub 2015/04/04. doi:
1738 10.4314/ahs.v15i1.7. PubMed PMID: 25834530; PubMed Central PMCID:
1739 PMCPmc4370121.
- 1740 32. Chang LW, Nakigozi G, Billioux VG, Gray RH, Serwadda D, Quinn TC, et al.
1741 Effectiveness of Peer Support on Care Engagement and Preventive Care
1742 Intervention Utilization Among Pre-antiretroviral Therapy, HIV-Infected Adults in
1743 Rakai, Uganda: A Randomized Trial. AIDS and Behavior. 2015;19(10):1742-51. doi:
1744 10.1007/s10461-015-1159-y.
- 1745 33. Chan AK, Ford D, Namata H, Muzambi M, Nkhata MJ, Abongomera G, et al. The
1746 Lablite project: A cross-sectional mapping survey of decentralized HIV service
1747 provision in Malawi, Uganda and Zimbabwe. BMC health services research. 2014;14.
1748 doi: 10.1186/1472-6963-14-352. PubMed PMID: WOS:000340917700001.
- 1749 34. Sibanda EL, Bernays S, Weller IV, Hakim JG, Cowan FM. Manuscript title:
1750 Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a
1751 qualitative study from Harare, Zimbabwe. BMC public health. 2015;15:784. Epub
1752 2015/08/16. doi: 10.1186/s12889-015-2136-0. PubMed PMID: 26276143; PubMed
1753 Central PMCID: PMCPmc4536866.
- 1754 35. Mwambete KD, Kamuhabwa AA. Resistance of commensal intestinal Escherichia coli
1755 and other enterics to co-trimoxazole and commonly used antibiotics in HIV/AIDS
1756 patients. Clinical Microbiology: Open Access. 2013.
- 1757 36. Kamuhabwa AA, Gordian R, Mutagonda RF. Implementation of co-trimoxazole
1758 preventive therapy policy for malaria in HIV-infected pregnant women in the public
1759 health facilities in Tanzania. Drug, healthcare and patient safety. 2016;8:91-100.
1760 Epub 2016/12/23. doi: 10.2147/dhps.s119073. PubMed PMID: 28008284; PubMed
1761 Central PMCID: PMCPmc5167525.
- 1762 37. Louwagie G, Girdler-Brown B, Odendaal R, Rossouw T, Johnson S, Van der Walt M.
1763 Missed opportunities for accessing HIV care among Tshwane tuberculosis patients
1764 under different models of care. Int J Tuberc Lung Dis. 2012;16(8):1052-8. doi:
1765 10.5588/ijtld.11.0753. PubMed PMID: WOS:000306678800012.
- 1766 38. Okot-Chono R, Mugisha F, Adatu F, Madraa E, Dlodlo R, Fujiwara P. Health system
1767 barriers affecting the implementation of collaborative TB-HIV services in Uganda. Int
1768 J Tuberc Lung Dis. 2009;13(8):955-61.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1769 39. Naikoba S, Senjovu KD, Mugabe P, McCarthy CF, Riley PL, Kadengye DT, et al.
1770 Improved HIV and TB Knowledge and Competence among Mid-level Providers in a
1771 Cluster-Randomized Trial of One-on-One Mentorship for Task Shifting. *Journal of*
1772 *Acquired Immune Deficiency Syndromes*. 2017;75(5):e120-e7. doi:
1773 10.1097/QAI.0000000000001378.
- 1774 40. Luyirika E, Towle MS, Achan J, Muhangi J, Senyimba C, Lule F, et al. Scaling Up
1775 Paediatric HIV Care with an Integrated, Family-Centred Approach: An Observational
1776 Case Study from Uganda. *PLoS ONE*. 2013;8(8). doi:
1777 10.1371/journal.pone.0069548. PubMed PMID: WOS:000324401500013.
- 1778 41. Ansa GA, Walley JD, Siddiqi K, Wei X. Delivering TB/HIV services in Ghana: a
1779 comparative study of service delivery models. *Transactions of the Royal Society of*
1780 *Tropical Medicine and Hygiene*. 2014;108(9):560-7. doi: 10.1093/trstmh/tru110.
1781 PubMed PMID: WOS:000343059500009.
- 1782 42. Horwood C, Haskins L, Vermaak K, Phakathi S, Subbaye R, Doherty T. Prevention of
1783 mother to child transmission of HIV (PMTCT) programme in KwaZulu-Natal, South
1784 Africa: an evaluation of PMTCT implementation and integration into routine maternal,
1785 child and women's health services. *Tropical Medicine and International Health*.
1786 2010;15(9):992-9. Epub 2010/06/22. doi: 10.1111/j.1365-3156.2010.02576.x.
1787 PubMed PMID: 20561313.
- 1788 43. Adepoju AV, Ogbudebe CL, Adejumo OA, Okolie J, Inegbeboh JO. Implementation
1789 of Isoniazid Preventive Therapy among People Living with HIV in Northwestern
1790 Nigeria: Completion Rate and Predictive Factors. *J Glob Infect Dis*. 2020;12(2):105-
1791 11. Epub 2020/08/11. doi: 10.4103/jgid.jgid_138_18. PubMed PMID: 32773999;
1792 PubMed Central PMCID: PMC7384686.
- 1793 44. Aisu T, Raviglione MC, Eriki P, Narain J, Barugahare L, Tembo G, et al. Preventive
1794 chemotherapy for HIV-associated tuberculosis in Uganda: an operational
1795 assessment at a voluntary counselling and testing centre. *AIDS*. 1995;9(3):267-73.
- 1796 45. Catalani C, Green E, Owiti P, Keny A, Diero L, Yeung A, et al. A Clinical Decision
1797 Support System for Integrating Tuberculosis and HIV Care in Kenya: A Human-
1798 Centered Design Approach. *PLoS ONE*. 2014;9(8). doi:
1799 10.1371/journal.pone.0103205. PubMed PMID: WOS:000341127500009.
- 1800 46. Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, et al. The
1801 implementation of isoniazid preventive therapy in HIV clinics: the experience from the
1802 TB/HIV in Rio (THRio) study. *AIDS*. 2010;24(Suppl 5):S49.
- 1803 47. Faust L, Ruhwald M, Schumacher S, Pai M. How are high burden countries
1804 implementing policies and tools for latent tuberculosis infection? A survey of current
1805 practices and barriers. *Health Sci Rep*. 2020;3(2):e158. Epub 2020/05/07. doi:
1806 10.1002/hsr2.158. PubMed PMID: 32373716; PubMed Central PMCID:
1807 PMC7196590.
- 1808 48. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al.
1809 Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in
1810 Botswana. *PLoS ONE*. 2011;6(4):e18435.
- 1811 49. Huerga H, Mueller Y, Ferlazzo G, Mpala Q, Bevilacqua P, Vasquez B, et al.
1812 Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test
1813 Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected
1814 Patients in Resource-Constrained Settings. *JAIDS*. 2016;71(4):e89-95. Epub
1815 2016/02/26. doi: 10.1097/qai.0000000000000895. PubMed PMID: 26910386.
- 1816 50. Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It's about my life":
1817 facilitators of and barriers to isoniazid preventive therapy completion among people

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1818 living with HIV in rural South Africa. *AIDS Care*. 2017;29(7):936-42. doi:
1819 10.1080/09540121.2017.1283390. PubMed PMID: WOS:000402669100019.
- 1820 51. Jarrett BA, Woznica DM, Tilchin C, Mpungose N, Motlhaoleng K, Golub JE, et al.
1821 Promoting Tuberculosis Preventive Therapy for People Living with HIV in South
1822 Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced
1823 Patient-Provider Dynamics. *AIDS and Behavior*. 2019;24(4):1106-17. doi:
1824 10.1007/s10461-019-02675-6. PubMed PMID: WOS:000520707300012.
- 1825 52. Khan FA, Verkuijl S, Parrish A, Chikwava F, Ntuny R, El-Sadr W, et al. Performance
1826 of symptom-based tuberculosis screening among people living with HIV: not as great
1827 as hoped. *AIDS*. 2014;28(10):1463-72. doi: 10.1097/qad.0000000000000278.
1828 PubMed PMID: WOS:000337705400009.
- 1829 53. Lai J, Dememew Z, Jerene D, Abashawl A, Feleke B, Teklu AM, et al. Provider
1830 barriers to the uptake of isoniazid preventive therapy among people living with HIV in
1831 Ethiopia. *Int J Tuberc Lung Dis*. 2019;23(3):371-7. Epub 2019/03/16. doi:
1832 10.5588/ijtld.18.0378. PubMed PMID: 30871669; PubMed Central PMCID:
1833 PMC6822021.
- 1834 54. Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, et
1835 al. Barriers to implementation of isoniazid preventive therapy in HIV clinics: A
1836 qualitative study. *AIDS*. 2010;24(SUPPL. 5):S45-S8. doi:
1837 10.1097/01.aids.0000391021.18284.12.
- 1838 55. Little KM, Khundi M, Barnes GL, Ngwira LG, Nkhoma A, Makombe S, et al.
1839 Predictors of isoniazid preventive therapy completion among adults newly diagnosed
1840 with HIV in rural Malawi. *Int J Tuberc Lung Dis*. 2018;22(4):371-7. Epub 2018/03/23.
1841 doi: 10.5588/ijtld.16.0836.
- 1842 56. McRobie E, Wringe A, Nakiyingi-Miiró J, Kiweewa F, Lutalo T, Nakigozi G, et al. HIV
1843 policy implementation in two health and demographic surveillance sites in Uganda:
1844 Findings from a national policy review, health facility surveys and key informant
1845 interviews. *Implementation Science*. 2017;12(1). doi: 10.1186/s13012-017-0574-z.
- 1846 57. Meribe SC, Adamu Y, Adebayo-Abikoye E, Lawal I, Amazue-Ezeuko I, Okeji N, et al.
1847 Sustaining tuberculosis preventive therapy scale-up through direct supportive
1848 supervision. *Public Health Action*. 2020;10(2):60-3. Epub 2020/07/09. doi:
1849 10.5588/pha.20.0003. PubMed PMID: 32639481; PubMed Central PMCID:
1850 PMC67316438.
- 1851 58. Mindachew M, Deribew A, Tessema F, Biadgilign S. Predictors of adherence to
1852 isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
1853 *BMC public health*. 2011;11(1):916.
- 1854 59. Mugomeri E, Olivier D, van den Heever WMJ. Tracking the rate of initiation and
1855 retention on isoniazid preventive therapy in a high human immunodeficiency virus
1856 and tuberculosis burden setting of Lesotho. *Southern African Journal of Infectious
1857 Diseases*. 2019;34(1). doi: 10.4102/sajid.v34i1.10. PubMed PMID:
1858 WOS:000519626300001.
- 1859 60. Munseri P, Talbot E, Mtei L, Fordham von Reyn C. Completion of isoniazid
1860 preventive therapy among HIV-infected patients in Tanzania. *Int J Tuberc Lung Dis*.
1861 2008;12(9):1037-41.
- 1862 61. Ngamvithayapong J, Uthairavavit W, Yanai H, Akarasewi P, Sawanpanyalert P.
1863 Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang
1864 Rai, Thailand. *AIDS*. 1997;11(1):107-12.
- 1865 62. Reddy MM, Thekkur P, Ramya N, Kamath PBT, Shastri SG, Kumar RBN, et al. To
1866 start or to complete? - Challenges in implementing tuberculosis preventive therapy

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1867 among people living with HIV: a mixed-methods study from Karnataka, India. Glob
1868 Health Action. 2020;13(1):1704540. Epub 2020/01/16. doi:
1869 10.1080/16549716.2019.1704540. PubMed PMID: 31937200; PubMed Central
1870 PMCID: PMCPMC7006687.
- 1871 63. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, Pronyk PM.
1872 Adherence to TB preventive therapy for HIV-positive patients in rural South Africa:
1873 implications for antiretroviral delivery in resource-poor settings? Int J Tuberc Lung
1874 Dis. 2005;9(3):263-9. Epub 2005/03/25. PubMed PMID: 15786888.
- 1875 64. Selehelo K, Makhado L, Madiba KA. Provision of Isoniazid Preventive Therapy: The
1876 Experiences of People Living with HIV. African Journal of Nursing and Midwifery.
1877 2019;21(2). doi: 10.25159/2520-5293/6221. PubMed PMID:
1878 WOS:000532581600019.
- 1879 65. Szakacs TA, Wilson D, Cameron DW, Clark M, Kocheleff P, Muller FJ, et al.
1880 Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in
1881 South Africa. BMC infectious diseases. 2006;6(1):97.
- 1882 66. Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, et al.
1883 Predictors of isoniazid preventive therapy completion among HIV-infected patients
1884 receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care.
1885 2019;32(1):119-27. doi: 10.1080/09540121.2019.1619661. PubMed PMID:
1886 WOS:000498969900018.
- 1887 67. Van Ginderdeuren E, Bassett J, Hanrahan C, Mutunga L, Van Rie A. Health system
1888 barriers to implementation of TB preventive strategies in South African primary care
1889 facilities. PLoS ONE. 2019;14(2):e0212035. Epub 2019/02/15. doi:
1890 10.1371/journal.pone.0212035. PubMed PMID: 30763378; PubMed Central PMCID:
1891 PMCPMC6375590.
- 1892 68. Wambiya EOA, Atela M, Eboreime E, Ibisomi L. Factors affecting the acceptability of
1893 isoniazid preventive therapy among healthcare providers in selected HIV clinics in
1894 Nairobi County, Kenya: a qualitative study. BMJ Open. 2018;8(12):e024286. Epub
1895 2018/12/24. doi: 10.1136/bmjopen-2018-024286. PubMed PMID: 30573488; PubMed
1896 Central PMCID: PMCPMC6303693.
- 1897 69. The World Bank. World Bank country and lending groups 2021. Available from:
1898 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
1899 [country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups).
- 1900 70. Kates J, Wexler A, Lief E. Donor government funding for HIV in low-and middle-
1901 income countries in 2019 2020. Available from: [https://files.kff.org/attachment/Donor-](https://files.kff.org/attachment/Donor-Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf)
1902 [Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf](https://files.kff.org/attachment/Donor-Government-Funding-for-HIV-in-Low-and-Middle-Income-Countries-in-2019.pdf).
- 1903 71. Assefa Y, Gilks CF. Ending the epidemic of HIV/AIDS by 2030: Will there be an
1904 endgame to HIV, or an endemic HIV requiring an integrated health systems response
1905 in many countries? International Journal of Infectious Diseases. 2020;100:273-7. doi:
1906 <https://doi.org/10.1016/j.ijid.2020.09.011>.
- 1907 72. Luboga SA, Stover B, Lim TW, Makumbi F, Kiwanuka N, Lubega F, et al. Did
1908 PEPFAR investments result in health system strengthening? A retrospective
1909 longitudinal study measuring non-HIV health service utilization at the district level.
1910 Health Policy Plan. 2016;31(7):897-909. Epub 2016/03/27. doi:
1911 10.1093/heapol/czw009. PubMed PMID: 27017824.
- 1912 73. Mikkelsen E, Hontelez JA, Jansen MP, Bärnighausen T, Hauck K, Johansson KA, et
1913 al. Evidence for scaling up HIV treatment in sub-Saharan Africa: a call for
1914 incorporating health system constraints. PLoS medicine. 2017;14(2):e1002240.

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1915 74. Vitoria M, Granich R, Banda M, Fox MY, Gilks C. Implementation of co-trimoxazole
1916 prophylaxis and isoniazid preventive therapy for people living with HIV. Bulletin of the
1917 World Health Organization. 2010;88:253-9.
- 1918 75. Kunkel A, Colijn C, Lipsitch M, Cohen T. How could preventive therapy affect the
1919 prevalence of drug resistance? Causes and consequences. Philosophical
1920 Transactions of the Royal Society B: Biological Sciences. 2015;370(1670):20140306.
- 1921 76. Kafu C, Wachira J, Braitstein P, Wilson I, Koech B, Kamene R, et al. Provider
1922 perspectives on the role of the patient as an active participant in HIV care. Global
1923 public health. 2020;1-11. doi: 10.1080/17441692.2020.1830296.
- 1924 77. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial
1925 Susceptibility Testing, 31th Edition: CLSI; 2020 [cited 35]. 1-332]. Available from:
1926 <https://clsi.org/standards/products/microbiology/documents/m100-preorder/>.
- 1927 78. Ersoy SC, Heithoff DM, Barnes Lt, Tripp GK, House JK, Marth JD, et al. Correcting a
1928 Fundamental Flaw in the Paradigm for Antimicrobial Susceptibility Testing.
1929 EBioMedicine. 2017;20:173-81. Epub 2017/05/29. doi: 10.1016/j.ebiom.2017.05.026.
1930 PubMed PMID: 28579300.
- 1931 79. Zachariah R, Massaquoi M. Cotrimoxazole prophylaxis for HIV-positive TB patients in
1932 developing countries. Tropical doctor. 2006;36(2):79-82.
- 1933 80. Mansoor L, Dowse R. Written medicines information for South African HIV/AIDS
1934 patients: does it enhance understanding of co-trimoxazole therapy? Health Education
1935 Research. 2006;22(1):37-48. doi: 10.1093/her/cyl039.
- 1936 81. Kenny T, Wilson R, Purves I, Clark Sr J, Newton L, Newton D, et al. A PIL for every
1937 ill? Patient information leaflets (PILs): a review of past, present and future use.
1938 Family Practice. 1998;15(5):471-9. doi: 10.1093/fampra/15.5.471.
- 1939 82. Hauck K, Morton A, Chalkidou K, Chi Y-L, Culyer A, Levin C, et al. How can we
1940 evaluate the cost-effectiveness of health system strengthening? A typology and
1941 illustrations. Social science & medicine. 2019;220:141-9. doi:
1942 10.1016/j.socscimed.2018.10.030.
- 1943 83. Steurs L, Orbie J, Delputte S, Verschaeve J. EU Donors and health system
1944 strengthening: the love-hate relationship with the Global Fund. Development Studies
1945 Research. 2018;5(sup1):S1-S13.
- 1946 84. USAID. USAID's vision for health systems strengthening 2030: Author Washington,
1947 DC; 2021. Available from:
1948 https://www.usaid.gov/sites/default/files/documents/USAID_OHS_VISION_Report_FINAL_single_5082.pdf.
1949
- 1950 85. World Health Organization. Healthy systems for universal health coverage: a joint
1951 vision for healthy lives 2018. Available from:
1952 https://www.uhc2030.org/fileadmin/uploads/uhc2030/Documents/About_UHC2030/mgt_arrangements_docs/UHC2030_Official_documents/UHC2030_vision_paper_WEB_2.pdf.
1953
1954
- 1955 86. Global Fund. The Global Fund Strategy 2017–2022: investing to end epidemics:
1956 Reliefweb; 2017. Available from:
1957 https://www.theglobalfund.org/media/2531/core_globalfundstrategy2017-2022_strategy_en.pdf.
1958
- 1959 87. USAID. ADS Chapter 220: Use and Strengthening of Reliable Partner Government
1960 Systems for Implementation of Direct Assistance 2014. Available from: <https://2012-2017.usaid.gov/sites/default/files/documents/1868/220.pdf>.
1961

Implementation of cotrimoxazole and isoniazid – preventive therapies for people with HIV.

- 1962 88. Rwabukwisi FC, Bawah AA, Gimbel S, Phillips JF, Mutale W, Drobac P. Health
1963 system strengthening: a qualitative evaluation of implementation experience and
1964 lessons learned across five African countries. BMC health services research.
1965 2017;17(3):77-89.

1966 Supporting information

1967 Tables

1968 Table 1. Main characteristics of the studies included in this review.

1969 Table 2. List of facilitators for the implementation of CPT and IPT.

1970 Figures

1971 Fig 1. PRISMA Flow Diagram.

1972 Fig 2. Regional representation of countries included in this review.

1973 Fig 3. Metasummary: Barriers to cotrimoxazole preventive therapy for people living with HIV.

1974 Fig 4. Metasummary: Barriers to isoniazid preventive therapy for people living with HIV.

1975 Fig 5. The preventive therapy cascade.

1976 Additional files

1977 S1 Additional file. PICO Framework (Modified PICO).

1978 S2 Additional file. Systematic review protocol.

1979 S3 Additional file. PRISMA checklist.

1980 S4 Additional file. Database searches and results.

1981 S5 Additional file. Mixed method quality appraisal tool (MMAT) and user guide.

1982 S6 Additional file. Detailed description of studies included in this review.

1983 S7 Additional file. Assessment of methodological strengths and limitations.

1984 S8 Additional file. Metasummary tables.

PRISMA 2009 Flow Diagram